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THE EFFECT OF ACTIVATION INDUCED CYTIDINE DEAMINASE PHOSPHORYLATION
AND HERPES VIRUS URACIL DNA GLYCOSYLASE ON ANTIBODY DIVERSIFICATION
Marc Daniel Macaluso, Ph.D.
Supervisory Professor: Kevin M. McBride, Ph.D.

Activation-induced cytidine deaminase (AID) is a mutagenic enzyme that is
expressed in mammalian B-cells and initiates the antibody diversification processes of
somatic hypermuntation (SHM) and isotype class switch recombination (CSR). AID is
targeted to the immunoglobulin gene locus where it deaminates cytosines to generate uracil
residues in DNA. This generates guanine-uracil (U:G) mismatch lesion which are recognized
by uracil DNA glycosylase (UNG), a DNA repair enzyme that removes uracil from DNA and
triggers downstream repair of the lesion. While UNG is a ubiquitously expressed DNA repair
enzyme, its recognition and removal of AID introduced uracils is essential in both SHM and
CSR. Mice lacking AID or UNG are deficient in SHM and CSR resulting in a compromised
immune system.
Due to its mutagenic activity AID is heavily regulated by diverse mechanisms
including post-translational modification. Here we investigate the effect of AID
phosphorylation in CSR, and identify potential phospho-AID interacting factors. Using an in
vitro CSR assay we show that preventing AID phosphorylation at novel sites threonine-150,
serine-169 and tyrosine-184 significantly reduces CSR efficiency. We identified potential
phospho-AID binding proteins using a protein domain array screen, which may prove to be
important in modulating AID activity.
Herpes viruses posses a large double stranded DNA genome and many carry a form
of uracil DNA glycosylase. Many of these viruses, such as Epstein-Barr virus (EBV), infect
mammalian B-cells. Our experiments show that viral UNGs are able to partially restore CSR
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when expressed in B-cells from Ung deficient mice. Intriguingly we discovered that viral
UNGs suppress CSR when expressed in wild-type B-cells, and that UNG catalytic activity is
not required for this suppressive effect. We also found that viral UNG expression in mouse
B-cells reduces the frequency of AID induced IgH-cMYC translocations, suggesting that viral
UNG may play a role in protecting the host cell genome from damage. These studies have
revealed a novel mechanism by which herpes viruses might impede the host immune
system.
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Chapter 1 - Introduction
1.1 Adaptive Immunity and the Antibody Diversification Processes
B-cells and the antibodies they produce are one of the primary mechanisms used by
the mammalian immune system to respond to infections such as parasites, bacteria and
viruses. B-cells are also one of the two cell types that are responsible for adaptive immunity
and immunological memory. They generate an antibody repertoire with the ability to
recognize a diverse spectrum of antigens as well as several different effector functions
through three distinct mechanisms. V(D)J recombination is a process that occurs in the bone
marrow involving different gene segments of the immunoglobulin variable region that are
recombined stochastically to produce unique combinations of the antibody variable region.
The second major process known as somatic hypermutation (SHM), involves the deliberate
introduction of random mutations into the previously recombined V(D)J region, greatly
increasing the antigen recognition potential of the immune system (Delker, 2009). The third
mechanism of antibody diversification is Isotype Class Switch Recombination (CSR)
whereby the antigen binding specificity of the antibody remains the same but the isotype
class of the constant region is changed thus allowing for a differential response from
immune system to the same antigen (McHeyzer-Williams and McHeyzer-Williams, 2005).
Both SHM and CSR occur in mature B-cells found in the secondary lymphoid tissues and
both are initiated at the molecular level by unique mechanisms that involve of self-induced
DNA damage. A mutagenic enzyme known as Activation Induced Cytidine Deaminase
(AID) is recruited to the Ig locus to initiate both the SHM and CSR process (Delker, 2009).
For reasons that are not yet fully understood AID-induced DNA damage in B-cells is not
repaired in a high fidelity manner. Taken together these three immunological diversification
mechanisms allow the immune system to produce a diverse antibody repertoire that is
capable of identifying and adapting to novel antigens, and able to stimulate a response from
the different branches of the immune system.
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1.2 V(D)J recombination
The germ line immunoglobulin gene consists of both heavy and light chain loci that
encode multiple copies of nonfunctional gene segments. The heavy chain locus contains
three types of gene segments, the variable(V) , the diversity(D) , and the joining(J)
segment. While the light chain locus only contains variable(V) and joining(J) gene segments.
In order to make a functional immunoglobulin gene locus these gene segments must be
reordered in a process called V(D)J recombination that occurs during B-cell development in
the bone marrow (Schatz and Ji, 2011). The human heavy chain locus is located on
chromosome 14 and each chromosome contains approximately 123-129 variable, 27
diversity, and 9 joining segments (Watson, 2013) and in order to produce an expressible
immunoglobulin variable region one gene segment from each type must be brought together
to form a functional V(D)J exon. The V(D)J recombination process is initiated by protein
complex containing recombination activating gene 1 and 2 (RAG1,RAG2) that targets and
cleaves DNA at a RAG recombination signal that flank both ends of the V, D and J
segments (Schatz and Ji, 2011). These double strand breaks (DSBs) are then repaired by
the classical non-homologous end joining (NHEJ) pathway. The Immunoglobulin heavy
chain (IgH) locus is processed first and upon its successful recombination the
Immunoglobulin light chain (IgL) locus is then processed. This gene recombination connects
the V, D and J segments resulting in a functional V(D)J exon. This recombined V(D)J exon
is then expressed along with the constant region exon to produce a functional B-cell
receptor (BCR). Non-productive V(D)J gene rearrangements are also possible such as gene
inversion, gene duplication, and translocations. Normally translocations trigger programed
cell death, however it is possible for some translocation events from V(D)J recombination,
such as Bcl2-IgG fusion, to lead to B-cell lymphomas (Schatz and Ji, 2011). After successful
V(D)J recombination and BCR expression the cells are considered naïve adult B-cells and
leave the bone marrow to infiltrate the periphery.
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1.3 Somatic Hypermutation
The random assortment of V(D)J gene segments during B-cell development in the
bone marrow provides some limited diversification to the antibody binding repertoire, but
these antibodies are ultimately only able to recognize a finite number of antigens. However
the antigen binding repertoire can be greatly expanded through a secondary process known
as somatic hypermutation in which the antigen binding domain is actively mutated, thereby
altering the affinity and specificity for a given antigen. After naïve B-cells enter the periphery
they, along with T-cells, are attracted to the secondary lymphoid tissues by CXCL13 that is
secreted by follicular dendritic cells (Cyster, 2010). Once B-cells have entered the
secondary lymphoid tissue they enter a sub-structure known as the germinal center (GC)
where B-cells both proliferate and begin the somatic hypermutation process. The expression
of AID, the initiating factor of SHM, is highly restricted and requires direct stimulation from T
helper cell contact via the CD40-CD40L signaling pathway. Once AID is expressed in GC Bcells it is targeted to the V(D)J region of the Ig locus during gene transcription, potentially by
interaction with PCNA, where it deaminates cytosine residues to produce uracils (Delker,
2009). While most uracils present in DNA are repaired in a high fidelity fashion by the Base
Excision Repair (BER) pathway, uracils introduced into the Ig locus by AID are not. Error
prone DNA polymerases are recruited to the Ig locus where they replicate the DNA
introducing mutations in the process. The molecular mechanisms that suppress classical
high fidelity repair, and lead to the recruitment of low fidelity factors are still largely unknown.
After the random mutation of the variable region in the somatic hypermutation process GC
B-cells then compete for survival signals in a process known as clonal selection. First the
GC B-cells compete for the ability to bind to antigens that are presented by follicular
dendritic cells. GC B-cells that have a strong binding affinity for antigen will receive prosurvival signals through their B-cell receptor, while GC B-cells that have low antigen binding
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affinity will not receive those survival signals and be deleted (Shlomchik and Weisel, 2012).
After GC B-cells have successfully competed for and bound antigen they internalize the
antigen, digest it into peptides and present it to T-helper cells via Major Histocompatibility
Complex II (MHCII) (Shlomchik and Weisel, 2012). B-cells that are reactive to self-antigen
are deleted by the T-helper cells, those that are not are given survival and proliferation
signals by the T-helper cells. B-cells that bind to antigen with high affinity and have received
the proper signals from T-helper cells then go on to proliferate and differentiate into longlived memory B-cells or effector plasma cells that actively secrete antibody.
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Figure 1
A Depiction of the Somatic Hypermutation Process at the Immunoglobulin Heavy
Chain (IgH) Locus
AID is expressed in germinal center B-cells and is targeted to the V(D)J exon of the
IgH locus. During transcription of the V(D)J exon AID deamininates cytosine to uracil in
single stranded DNA introducing mutations into the gene sequence. Uracil DNA Glycosylase
(UNG) scans the Ig locus detects and removes the uracils introduced by AID leaving an
abasic site. Error prone polymerases are then recruited to the locus which repair the locus
by low fidelity replication, thereby introducing more mutations into the V(D)J exon. The
mutations at the V(D)J exon lead to changes in protein primary sequence and tertiary
structure of the antigen binding portion of the antibody, thus diversifying the spectrum of
potential antigens that can be recognized.
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1.4 Class Switch Recombination
Mammalian antibodies are categorized into five different isotypes depending on the
structure of their constant region domain, the portion of the protein that allows for differential
effector function; the stimulation of the immune system in response to the antigen
recognized by the variable region of the antibody. The Ig locus consists of two main types of
exons, the variable region exon that is made functional after successful V(D)J
rearrangement, and constant region exons that code for the constant region of the protein.
The transcription of the Ig locus is regulated in such a way that the immediate downstream
constant region exon is spliced to the variable region exon to produce a mature mRNA
transcript. In the germ line gene arrangement of the Ig gene the μ exon is immediately down
stream of the variable region exon, followed by the δ exon. Thus all naïve B-cells start as
IgM or IgD, differential splicing regulates the expression of these two constant region exons
in naïve B-cells. In order for B-cells to express any other immunoglobulin isotype they must
undergo Class Switch Recombination (CSR), a process in which the Ig gene locus is
rearranged and a new constant region exon is moved to the adjacent downstream position.
AID deamination is also the first step of the CSR process, although it is targeted to another
region of the Ig locus known as switch regions. Switch regions are long stretches of GC rich
tandem repeat DNA located between the constant region exons. The CSR process is
initiated by stimulation from external signals that lead to AID expression, the transcription of
specific switch regions, and the targeting of AID to those actively transcribed switch regions.
AID induced uracils at the actively transcribed switch regions are processed by uracil DNA
glycosylase (UNG), this then leads to two double strand breaks and non-homologous end
joining between different switch regions, deleting the intervening sequence in the process
(Fig. 2). The end result of this is the insertion of a new constant region exon adjacent to the
variable region exon, thus resulting in the expression of a new antibody isotype in that cell.
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How UNG processing of AID induced uracils at the switch region initiates double strand
breaks in this process has yet to be resolved.
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Figure 2
Class Switch Recombination Process at the IgG Locus
During normal Ig heavy chain expression the V(D)J exon is expressed, spliced to
adjacent to the “C” constant region exon, producing a functional antibody upon translation.
During the Class Switch Recombination process AID deaminates switch regions between
the V(D)J and the first constant region exon (Cμ) and switch regions between C exons.
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1.5 Activation Induced Cytidine Deaminase
AID belongs to the APOBEC gene family of deaminases, enzymes that possess the
ability to deaminate cytosine to uracil in RNA and DNA. While AID functions in adaptive
immunity it is one of the oldest members of the gene family, suggesting it may have other
functions (Conticello, 2008). Other APOBEC family members preform different functions.
The gene family is named after apolipoprotein B editing complex 1 (APOBEC1) which
functions as an mRNA editing enzyme that deaminates apolipoprotein B transcripts
introducing a stop codon (Conticello, 2008). This mRNA editing of apolipoprotein B serves
as a mechanism of regulating lipid uptake in the intestines. APOBEC3 serves as an
intracellular anti-retroviral defense system, introducing mutations into retroviral RNA as the
virus attempts to replicate in host cells (Conticello, 2008). AID is a single stranded DNA
deaminase that catalyzes the deamination of cytosine to uracil in DNA. AID was originally
discovered in the mouse B-cell lymphoma cell line CH12 which is known to be able to
efficiently undergo class switch recombination in vitro upon stimulation (Nakamura, 1996).
AID was discovered using a PCR screen to differentiate between transcripts that are
expressed in resting CH12 cells and transcripts that are only expressed when the cells are
exposed to switch stimulation (Muramatsu, 1999). An Aid knockout mouse line was soon
generated, B-cells from these mice showed a complete inability to undergo CSR in vitro and
in vivo, displaying a hyper-IgM phenotype (Muramatsu, 2000). These mice also showed an
inability to produce antibodies in response to inoculation, demonstrating the essential role of
AID in the SHM process (Muramatsu, 2000). The loss of AID in human patients results in a
rare genetic condition known as Hyper-IgM syndrome type 2. These patients have
compromised immune systems because their B-cells cannot under go CSR or SHM (Revy,
2000). While essential for a healthy immune system AID actively damages DNA and can
cause genomic instability. It has been demonstrated that AID is necessary for the formation
of the IgH-cMYC translocation, the oncogenic translocation that is the hallmark of Burkitt’s
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lymphoma, suggesting that AID deamination is the first step in the transformation process
(Ramiro, 2006). Due to its potential oncogenic activity AID is heavily regulated by a number
of different mechanisms, including cellular localization, transcriptional regulation through
microRNAs, and posttranslational modification (Delker, 2009). Many studies have shown
that AID is heavily regulated through posttranslational modification, particularly
phosphorylation. AID contains at least six serine/threonine phosphorylation sites and one
tyrosine phosphorylation site that have been detected by mass spectrometry (McBride,
2006). Of these sites the majority of research has been focused on Serine 38 and to a
lesser extent Serine 3. It has been suggested that serine 38 phosphorylation has a positive
regulatory effect on both class switch recombination as well as somatic hypermutation, as
mice that possess a S38A mutation show significant reduction in both processes (Cheng,
2009). Conversely phosphorylation of serine 3 of AID has been shown to be a negative
regulator of its activity. The S3A substitution mutation causes an increase in CSR levels, as
well as an increase in off target AID activity and c-myg/IgH translocations (Gazumyan,
2011).

1.6 DNA Glycosylases
DNA glycosylases are a large family of enzymes that excise damaged DNA bases as
part of the base excision repair pathway. They are found in E.coli up to higher eukaryotes. A
highly conserved mechanism of “base flipping” is used to remove the damaged base. They
are categorized into six super families based on their structure and crystal structures have
been solved for at least one protein from each family, showing that the six super families
evolved DNA glycosylase activity from different ancestral genes (Conticello, 2008).
Mammals have 11 DNA glycosylases, some recognize a specific substrate, while others are
capable of recognizing and removing multiple substrates (Conticello, 2008). Bases can be
damaged through a number of different chemical mechanisms. Oxidation can result in 8-
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oxoguanine, 5-hydroycytosine, or thymine glycol and alkylation can result in 3methylguanine or 3-methyladenine (Krokan and Bjoras, 2013). Deamination of adenine
results in hypoxanthine, and deamination of cytosine results in uracil. DNA glycosylases
have specificity for particular lesions as well as the context of DNA, single or double
stranded, in which the lesion is found (Krokan and Bjoras, 2013). Mammalian UNG is also
regulated by subcellular localization and are capable of acting on nuclear or mitochondrial
DNA. The mechanism of UNG localization is dependent on the presence of a mitochondrial
localization signal generated by alternate splicing (Krokan and Bjoras, 2013).
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Figure 3
Crystal Structure of
Human Uracil DNA
Glycosylase 2
A space filling model of
human UNG bound to
substrate analog 6-[4-[(3Carboxybenzylamino)butyl
amino]methyl]uracil (blue).
Two highly conserved
residues essential for
catalysis, Aspartic Acid154 in the water activating
loop, and Histidine-277 in
the DNA interacting
leucine loop, are
highlighted in yellow
(Mol, 1995).

1.7 Mammalian DNA Glycosylases
Uracil exist in double stranded DNA in two main forms U:G mismatches and U:A
pairs both of which are recognized and removed by uracil DNA glycosylases. U:A
mismatches occur due to the incorporation of free dUTP during DNA replication; dUTP
exists in the cytosol in small quantities and is necessary in pyrimidine metabolism pathways
(Krokan and Bjoras, 2013) . Free dUTP can be read by the replicative DNA polymerase as a
dTTP and incorporated across from an adenine during DNA replication. U:G mismatches
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occur in dsDNA when the amine group of cytosine is replaced with an oxygen, this
deamination results in a uracil. When read by a DNA polymerase a U:G mismatch will result
in a transition mutation C:G mutated to a A:T if the mismatch is not repaired before
replication. Uracil in mammalian DNA is recognized and removed by four monofunctional
DNA glycosylases methyl-CpG binding domain protein 4 (MBD4), Thymine DNA glycosylase
(TDG), Single-strand selective monofunctional uracil DNA glycosylase (SMUG), and UracilDNA glycosylase (UNG) (Krokan and Bjoras, 2013). MBD4 is capable of recognizing and
removing U:G and T:G mismatches in double stranded DNA and possesses a methyl-CpG
binding domain that targets its binding to methylated DNA (Krokan and Bjoras, 2013). MBD4
may play an important role in maintaining genomic integrity in the intestines as evidenced by
the loss of MBD4 in many colorectal cancers that show microsatellite instability (Riccio,
1999), (Howard, 2009). Thymine DNA glycosylase, as the name suggests is capable of
removing thymine from G:T and U:G mismatches in double stranded DNA. Interestingly the
deletion of Tdg in mice causes an embryonic lethal phenotype, most likely due to its
involvement in gene methylation during development (Cortazar, 2011). SMUG is capable of
recognizing U:G and U:A mismatches with a strong preference for single stranded DNA and
is thought to serve as a backup for other DNA glycosylases (Kavli, 2002).

1.8 Mammalian Uracil DNA Glycosylase (UNG)
UNG is the primary mammalian uracil DNA glycosylase. UNG exists in two isoforms
UNG1 and UNG2, both encoded by the same gene and regulated by alternate splicing of
the amino terminus (Krokan and Bjoras, 2013). UNG1 contains a mitochondrial localization
signal and is the only known mitochondrial DNA glycosylase. UNG2 is targeted to the
nucleus and contains both PCNA and RPA binding sites that are thought to target it to the
replication fork machinery so it can process uracils as they are incorporated into DNA during
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polymerization (Krokan and Bjoras, 2013). UNG is a globular enzyme consisting of eight
alpha helixes surrounding a centralized four stranded parallel beta sheet where the active
site groove is located (Mol, 1995). UNG detects uracils in double stranded DNA through
contact with the minor groove and a specific amino acid Leu 272 is essential for scanning
and contacting the DNA backbone (Mol, 1995). Once the enzyme encounters a uracil leu
272 penetrates the minor groove, bending the DNA slightly and flipping out the uracil from
the core of the double helix and into the binding pocket of the UNG active site (Mol, 1995).
The flipping of uracil base and the distortion of the DNA backbone by UNG causes strain in
the DNA, and once the uracil is situated in the binding pocket it is coordinated by catalytic
amino acids. The enzyme then changes conformation cleaving the glycosidic bond between
the uracil and the 1’-carbon of the deoxyribose base. A water molecule, coordinated by
aspartate 145 (in human UNG), makes a nucleophilic attack on the 1’-carbon replacing the
uracil with a hydroxyl group (Mol, 1995). The cleavage of this bond releases the strain and
distortion in the DNA backbone and leaves an abasic site and a free uracil. After cleavage
UNG remains tightly bound to the fragile abasic site that is later processed by downstream
pathways (Mol, 1995). It has been demonstrated that the substitution of key amino acids in
the catalytic motifs of the water activating loop (D147N), the uracil recognition strand
(N206V) and the leucine loop (H270L) can significantly reduce the glycosylase activity of
mouse UNG (Begum, 2007). While the combination of at least two of these mutations results
in the complete loss of UNG glycosylase activity (Di Noia, 2007). Genetic deletion of Ung in
mice shows that while they do not have a significant increase in genomic mutation or cancer
they do have a deficiency in adaptive immunity (Nilsen, 2000). When Ung null mice are
crossed to Smug1 and Msh2 double knockout have a significantly shorter lifespans and a
high prevalence of lymphomas, suggesting a high degree of redundancy to detect and
remove uracil from DNA (Kemmerich, 2012).
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1.9 Base Excision Repair
The recognition of a chemically damaged base by a DNA glycosylase is the first step
in the Base Excision Repair process. The chemically damaged base is recognized by a DNA
glycosylase which catalyzes the cleavage of the N-glycosydic bond between the base and
the 1’ carbon of the deoxyribose sugar leaving an abasic site (Krokan and Bjoras, 2013).
The abasic site is then further processed by cleaving the phosphodiester bond in the
backbone causing a single strand break. This nicking of the DNA backbone is catalyzed by
bifunctional DNA glycosylases, which possess both glycosylase and endonuclease catalytic
activity, or by an AP endonuclease that is recruited to the abasic site (Krokan and Bjoras,
2013). The single-strand break is then processed and repaired by either short patch repair,
where the missing nucleotide is replaced, or long patch repair where up to 10 adjacent
nucleotides are replaced (Krokan and Bjoras, 2013). The choice between short patch and
long patch repair depends on the initiating glycosylase, and cell type, and cofactors present.
Short patch repair is though to take place primarily in resting cells, after the glycosylase
removes the base AP endonuclease APE1 is recruited to nick and process the abasic site,
and then the abasic site is filled in by DNA pol β, and ligated by DNA ligase 1 or 3 (Fortini
and Dogliotti, 2007). Base excision repair occurs during DNA replication and utilizes many of
the same factors involved in DNA replication (Akbari, 2009). After AP endonuclease nicks
the strand the site is then processed by DNA pol β, or pol δ, depending on the original
glycosylase that recognized the legion (Tichy, 2011).

1.10 Base Excision Repair in B-cells
B-cells express the mutagenic AID that actively deaminates cytosines in the
immunoglobulin gene locus creating the mutations needed for antibody diversity (Delker,
2009). After AID deamination UNG2 is actively recruited to the Immunoglobulin locus where
it removes AID induced uracils (Delker, 2009). However AID induced uracils in the Ig locus
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are not repaired by the normal high fidelity BER pathway. Through mechanisms that are still
unknown low fidelity DNA polymerases are recruited to process abasic sites in the VDJ
region during the somatic hypermutation process, diversifying the mutation spectrum more
than simple U:G mismatches would (Diaz and Storb, 2003). UNG2 is also involved with
removing AID induced uracils at switch regions during the class switch recombination
process (Delker, 2009). The processing of these abasic sites leads to a double strand break
and non-homologous end joining. Thus B-cells from mice lacking UNG are almost
completely unable to undergo class switch recombination in vitro (Shen, 2006). The small
amount of cells able to switch is due to compensation from the MSH1/MSH2 pathway as
evidenced by Ung/Msh1/Msh2 triple knockout mice being completely unable to undergo
class switch (Shen, 2006).
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Figure 4
A Model for Class Switch Recombination and Somatic Hyper Mutation
A) The class switch recombination process is initiated by AID deamination adjacent of
cytosines on opposite strands at switch region loci. These uracils are then removed by UNG
or MSH2. The abasic sites are then nicked by AP endonuclease resulting in a double strand
break at the switch region leading the class switch recombination. B) Somatic
Hypermutation is initiated AID deamination in the switch regions. If the uracil is undetected it
will be read as a T during replication resulting in an A/T mutation (i). The uracil can be
detected by the MSH2/6 complex and processed by Exo1 (ii), the resulting sequence gap is
then replicated by error prone DNA polymerases such as pol η or pol ζ leading to transition
or transversion mutations (iv). The uracil can be detected and removed by UNG leaving an a
basic site, the abasic site can then be processed by AP endonuclease and then repaired by
pol β resulting in high fidelity repair (vi). The abasic site can also be repaired by translesion
synthesis where in Rev1 recruits error prone polymerases to the abasic site before or after
processing by AP endonuclease, resulting in the introduction of mutations (iii, v).
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1.11 Herpesviridae
Herpes viruses are a large family of viruses that infect a wide variety of host species
(Huff and Barry, 2003). They possess a linear double stranded DNA genome that encodes
for 100-200 genes, and a lipid bilayer envelope with membrane glycoproteins that they use
to gain entry to the host cell (Baer, 1984). After the virus enters the host cell the viral DNA
enters the nucleus, circularizes and begins transcribing viral genes (Young and Rickinson,
2004). Herpes viruses follow a pattern of infection usually involving an initial lytic infection
for the mucosal epithelium, the virus infects the host and an acute symptomatic infection can
occur during which the virus transcribes lytic genes (Young and Rickinson, 2004). After the
initial lytic stage of infection the virus enters its primary host cell end enters the latent stage
of its life cycle where it can persist asymptomatically for many years causing no symptoms
in the host (Young and Rickinson, 2004). Some herpes viruses are capable of reactivation
after long-term latency, which can lead to serious secondary conditions such as shingles or
cancer (Young, 1989). Herpes viruses are classified into three major subgroups Alpha, Beta,
and Gamma according to their rate of growth and, the primary cell of latent infection.
Alpha herpes viruses include human herpes simplex viruses 1, 2, and varicella
zoster virus. Both human herpes simplex viruses cause skin blisters at the site of infection,
HSV1 causes primarily oral “cold” sores and HSV2 casues genital herpes. While v.zoster
primary infection causes chicken pox resulting in red sores covering the body (Cohen,
2013). During the latent phase of the viral life cycle these viruses infect the neurons of the
peripheral ganglia where they remain for the lifespan of the host usually asymptomatically
(Grinde, 2013). However these viruses are capable of reactivation leading to herpes
outbreaks or in the case of varicella zoster reactivation results in shingles, a condition
characterized by skin rashes and severe pain caused by the virus damaging peripheral
neurons (Kawai, 2014).
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Beta herpes viruses infect and establish latency in leukocytes; the most thoroughly
studied and clinically relevant human beta herpes virus is cytomegalovirus (CMV). A
commonly occurring infection CMV usually produces no symptoms and remains latent.
However in patients with suppressed immune systems CMV reactivation can occur and lead
to serious conditions such as hepatitis, pneumonitis, and retinitis (Gupta, 2014), (Chiotan,
2014).
Gamma herpes viruses the third subfamily contains two human viruses Epstein-Barr
virus and Kaposi’s sarcoma virus, as well as mouse herpes virus 68 the standard laboratory
model. Gamma herpes viruses are transmitted orally or sexually and establish an acute
epithelial infection followed by a long-term latent infection in memory B-cells. Epstein-Barr
(EBV) perhaps the most well studied human herpes virus is known to cause acute
mononucleosis and is associated with several types of B-cell lymphoma (Young and
Rickinson, 2004). Kaposi’s sarcoma virus (KSV) was originally discovered in AIDS patients
during the 1990’s as the causative agent in the rare cancer Kaposi’s sarcoma (Chang,
1994). Both EBV and KSV infect host cells and evade the immune system through complex
mechanisms and contribute to the prevalence of several types of cancer worldwide.
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Table 1 – Known Human Herpes Viruses and Their Associated Pathologies
Cell type of
Common name
Number Subfamily
Associated diseases
latency
Herpes Simplex
HHV-1
α
Neuron
Oral/genital herpes
Virus 1
Herpes Simplex
HHV-2
α
Neuron
Oral/genital herpes
Virus 2
Varicella Zoster
HHV-3
α
Neuron
Chicken pox, shingles
Virus
Infectious mononucleosis,
post transplant lymphoma,
Epstein Barr Virus HHV-4
γ
B-cells
Hodgkin’s lymphoma, Burkitt’s
lymphoma, nasopharyngeal
carcinoma
Cytomegalovirus
HHV-5
β
Leukocytes Mononucleosis like syndrome
Human B
lumphotropic virus, HHV-6
β
T cells
Roseola infantum
Roseolovirus
HHV-7
β
T cells
Roseola infantum
Kaposi’s sarcoma, primary
Kaposi’s sarcoma
HHV-8
γ
B-cells
effusion lymphoma,
virus
Castleman’s disease
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1.12 EBV Life Cycle
Epstein-Barr virus is the most thoroughly studied of the gamma herpes virus family
due to its early discovery in 1964 and its association with a number of human diseases
(Epstein, 1964). It has been suggested that 90 – 95% of adults have been infected at some
point in their lives (Ascherio, 2001). Acute infection can cause infectious mononucleosis,
however the majority of infected individuals are asymptomatic (Young and Rickinson, 2004).
Transmitted orally EBV initially enters the host by infecting the epithelial cells of the oral
mucosa where the virus is thought to undergo lytic replication, shedding more virus into the
oropharynx (Fig. 5). The host immune system responds to the initial mucosal infection
whereby the virus is able to infect its main host cell type, mature B-cells (Anagnostopoulos,
1995). EBV enters host B-cells by binding to CD21 (also known as Complement type 2
receptor) and to the MHC-II molecules present on the cell surface (Nemerow, 1987). After
gaining entry into the host B-cell the EBV genome circularizes and enters the nucleus where
it remains episomally (Young and Rickinson, 2004). During the B-cell stage of the infection
the virus enters the latency III phase of its life cycle, where it activates a distinct gene
expression program to stimulate the host B-cells to proliferate, including 6 EBV nuclear
antigens (EBVNAs) and latent membrane proteins LMP-1, LMP-2A, and LMP-2B
(Anagnostopoulos, 1995). The infected B-cells then enter into the latency II gene expression
program which includes the expression of EBNA-LP, LMP-1, LMP-2, and induces the host
B-cells to differentiate into memory cells (Odumade, 2011). The host cell finally reaches the
latency I program where only viral gene expressed is EBNA-1, which simply replicates the
viral genome during host cell division (Humme, 2003). The EBNAs replicate the viral
genome and activate expression of other EBV genes (Young and Rickinson, 2004). LMP-1
expression actives the CD40 pathway, a signal normally provided by T-cells during the
germinal center selection process (Uchida, 1999). This leads to downstream activation of
NF-kB target genes such as anti-apoptotic Bcl-2 genes and AID and allows EBV infected
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cells to escape the normal negative selection process that takes place in germinal centers
(Henderson, 1991). LMP-2 mimics the activation of the B-cell Receptor pathway to stimulate
tyrosine kinase pathways leading to cell proliferation (Caldwell, 1998). In vitro infection of Bcells with EBV is capable of transforming cells into lymphoblast cell lines (LCL) that express
EBV latent cycle genes. Viral genome mutation studies have shown that EBNA2 and LMP-1
expression is essential for the in vitro transformation of B-cells (Rowe, 1987).
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Figure 5
The Cycle of Epstein-Barr Infection
A) The virus enters the host through the nasopharyngeal mucosa where the virus
establishes an acute primary infection and undergoes lytic replication and sheds virus. B)
The virus then infects peripheral B-cells where it goes into type III latency, activating all of
the EBNA’s and LMP’s C) Some of these infected B-cells make their way to the secondary
lymphoid tissue where they enter type II latency where they express LMP’s and EBNA-1, or
type I latency only expressing EBNA-1. D) Infected B-cells then enter the latency 0 stage,
where none of the viral genes are expressed, and can remain in this state for several
decades unless reactivated. E) Rarely these EBV infected B-cells may respond to an
infection and re-enter the germinal center and activate type I/II latency genes. F) The
reactivated infected cells can differentiate into memory or plasma cells and can be recruited
to the oral mucosa where they can enter they lytic stage of replication and begin shedding
virus.

24

1.13 Mouse Models of Gamma Herpes Virus Infection
Murine gamma herpes virus 68 is rodent herpes virus that has become the standard
model for studying gamma herpes virus family members in the laboratory. Originally isolated
from voles in northern Europe, MHV68 enters the host through the nasal epithelium and the
virus undergoes proliferation and replication in the lung during the acute phase of infection,
it then establishes acute infection in B-cells as well as T-cells where it causes a pathology
similar to human mononucleosis (Blaskovic, 1980). Germinal center B-cells are the main
host cell type during the latent phase of infection (Simas and Efstathiou, 1998). MHV68 has
been shown to cause lymphoproliferative disorders and high grade mixed T and B-cell
lymphomas (Sunil-Chandra, 1994). However, it has been suggested that MHV68 may only
play a role in initiating transformation of these cell since the viral genome was not detectable
in the majority of MHV68 associated lymphomas (Usherwood, 1996). The MHV68 genome
encodes for several genes that lead to host cell proliferation. Like KSV and EBV, MHV68
carries its own version of the anti-apoptotic protein bcl-2 that has been shown to interfere
with pro-apoptotic pathways, and inhibit apoptosis in vitro (Weck, 1997), and also encodes
for its own homolog of cyclin D, which it may use to stimulate host cell proliferation (Jung,
1994). MHV68 ORF-4 is homologious to host CD59 (Rother, 1994), a protein that inhibits
the complement membrane attack complex, and is likely used by the virus to evade the host
immune system. MHV68 also encodes for a uracil DNA glycolyase in ORF46 (Mackett,
1997). Like the other herpes viruses there is little known about the role viral UNG plays at
the lytic or latent stages of viral infection, if viral UNG helps maintain the host genome, or in
some way aids in manipulating host cell processes.
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1.14 Oncoviruses
Oncoviruses are viruses that are known to cause cancer in the host cells they infect.
There are seven known human oncoviruses that infect a variety of cell types and transform
them through direct and indirect mechanisms. Hepatitis B and C are both known to infect
hepatocytes and chronic infection can lead to hepatocellular carcinoma (El-Serag and
Rudolph, 2007). Hepatitis B is a DNA virus that is transmitted through bodily fluids or from
mother to child at the time of birth. Those infected before one year of age are highly
susceptible to developing chronic hepatitis, which may lead to hepatocellular carcinoma
later in life (Chang, 2007). Hepatitis B possesses a partially double stranded DNA genome,
but replicates its genome via reverse transcription (Beck and Nassal, 2007). It is not clear if
the hepatitis virus contributes to hepatocellular transformation directly, it is thought that
cancer arises after years of chronic liver inflation (Chang, 2007). In contrast the Hepatitis C
virus is a single stranded RNA virus that is transmitted sexually or through intravenous drug
use. While acute infection symptoms are usually mild, approximately 80% of cases develop
chronic infection and inflammation that can lead to cirrhosis and hepatocellular carcinoma
(Rosen, 2011).
Human papilloma virus (HPV) is a double stranded DNA virus that is responsible for
cancers of the cervix, genitals, tonsils and oropharynx (Schiffman and Castle, 2003). HPV
transforms host cells through direct two mechanisms, HPV protein E7 binds and sequesters
the tumors suppressor gene Rb which allows the transcription factor E2F to stimulate cell
cycle and proliferation (Ganguly and Parihar, 2009). While HPV protein E6 binds to tumor
suppressor p53, the major regulator of apoptosis, and primes it for ubiquitination via MDM2
E3 ligase and subsequent proteasomal degradation (Ganguly and Parihar, 2009). In 2005 a
vaccine for HPV was introduced to the market, which may lead to a signifigant reduction in
HPV associated cancers in the future (Who, 2009).
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Two human herpes viruses Epstein-Barr (HHV-4) and Kaposi’s sarcoma virus (HHV8) are known oncoviruses, and are known to cause a number of different malignancies in
the host they infect. Epstein-Barr virus (EBV) was the first identified human oncovirus
(Epstein, 1964). It is well documented that EBV infection is associated with the initiation and
progression of nasopharyngeal carcinoma and three types of lymphoma including Hodgkin’s
lymphoma, post-transplant lymphomas and Burkitt’s lymphoma, the tumor where the virus
was first identified in electron micrographs (Young and Rickinson, 2004). Although EBV
infection is associated with these three types of lymphoma, the viral genes expressed in
these tumor types can vary greatly (Young and Rickinson, 2004), (Epstein, 1964). EBV
infection is associated with approximately 40% of Hodgkin’s lymphoma cases in
industrialized countries and in EBV positive cases of Hodgkin’s lymphoma expression of
latent genes LMP1, LMP2 and EBNA1 has been found in Reed-Sternberg cells, a
characteristic cell type used to diagnose Hodgkin’s lymphoma (Portis, 2003). ReedSternberg cells are thought to be multinucleated B-cells that have gone through “failed”
germinal center reactions and have escaped negative selection (Portis, 2003). It has been
suggested that the expression of these viral genes allow these cells to bypass germinal
center selection since LMP-1 and LMP-2 mimic CD40 and BCR signaling respectively
(Young and Rickinson, 2004). EBV is also associated with B-cell lymphomas that arise in
immunosuppressed individuals, EBV genes can be detected in approximately 60% of
lymphomas in AIDS patients (Boshoff and Weiss, 2002). Post-transplant lymphomas (PTLs)
can arise after a bone marrow transplant, which severely suppresses the immune system
until the white blood cell population is able to regrow. PTLs usually occur within the first year
after allografting, and almost all of them express EBV latency genes EBVNA2 or LMP-1,
suggesting an important role for adaptive immunity in keeping latent EBV infections
suppressed (Young, 1989). Burkitt’s lymphoma is the cancer that is most commonly
associated with EBV infection. There are three main classifications of Burkitt’s lymphoma,
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endemic, sporadic and immunodeficiency associated. All forms of Burkitt’s lymphoma are Bcell lymphomas that are defined by a reciprocal translocation from the Ig locus to the cMYC
gene (Polack, 1996). The resulting chromosomal fusion drives over-expression of the cMYC
proto-oncogene, leading to proliferation and transformation. Burkitt’s lymphomas do not
show active expression of LMP-1 or EBNA2 like other EBV associated lymphomas, thus it
has been suggested that LMP-1 plays a role in the initiation Burkitt’s lymphoma and the
generation of the Ig-MYC translocation, but is later turned off (Kelly, 2002). EBV infection is
found in almost all cases of endemic Burkitt’s lymphoma, which effects children in West
Africa in areas where malaria is also endemic, while EBV is present in only a small number
of “sporadic” cases which are more common in the developed world (Brady, 2008). Lastly
Burkitt’s lymphoma can arise in patients with severe immune system deficiency, and AIDS
patients frequently. Perhaps the most famous example of this was David Vetter, the so
called bubble boy afflicted with severe combined immunodeficiency (SCIDs). He died of
Burkitt’s lymphoma 15 days after receiving a bone marrow transplant from his sister that was
later found to be contaminated with trace amounts of EBV (Aloj, 2012). Nasopharyngeal
carcinoma (NPC) is a rare cancer associated with EBV infection. It is most commonly found
in south East Asia where it has a peak prevalence of approximately 0.003% (Yu and Yuan,
2002). NPCs can show expression of EBNA1 as well as LMP1 and usually show an
undifferentiated pathology with a high amount of lymphocytic infiltrate which may be
involved in the progression of the tumor (Raab-Traub, 2002).
Kaposi’s sarcoma was first described in 1872 by Moritz Kaposi, however the herpes
virus that is now known to cause the disease was not discovered until 1994 (Chang, 1994).
The virus often leads to tumors in AIDS patients, where it was first identified; KSV infection
is normally asymptomatic in patients with a healthy immune system (Chang, 1994). The
virus itself has a high prevalence in Africa, and it is estimated 3 - 10% of the population in
the United States has been exposed to the virus that is thought to be spread by sexual
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transmission (Neipel, 1997b). Along with Kaposi’s sarcoma, KSV infection is also associated
with other malignancies such as primary effusion lymphoma and rare lymphoproliferative
disorder Castleman’s disease (Soulier, 1995). Castleman’s disease, also known as
agiofollicular lymph node hyperplasia, can be unicentric and confined to one lymph node, or
multicentric involving multiple sites throughout the body (Soulier, 1995). Unicentric
Castleman’s disease can normally be cured by the simple surgical removal of the afflicted
lymph node, while multicentric Castleman’s disease is a much more serious condition that
can involve organ malfunction due to hyperactivation of the immune-system and cytokine
overexpression (Fajgenbaum, 2014). Primary effusion lymphoma is a B-cell lymphoma
almost always associated with KSV infection and is primarily found in large body cavities
such as the abdominal of retroperitoneal cavity (Cesarman, 1995). All three KSV associated
diseases Kaposi’s sarcoma, Castleman’s disease, and Primary effusion lymphoma are also
associated with simultaneous HIV-AIDS infection, showing the importance of the immune
system in suppressing KSV associated pathology. KSV stimulates growth and
transformation of host cells through different pathways, KSV encodes a homolog of cyclin D
which when expressed can stimulate host cell cycle progression by interacting with host
cyclin dependent kinases such as Cdk6 (Cesarman, 1996). And like Epstein-Barr virus KSV
encodes a gene in ORF16 that is homologous to host bcl-2 and suppresses apoptosis by
binding to pro-apoptotic bcl-2 family members like Bax (Cai, 2010). Although KSV does
infect a wider variety of host cells than EBV does it also infects B-cells where it enters the
latent phase of its cycle. KSV encodes and expresses its own homolog of IL-6, a growth
factor known to stimulate the proliferation and differentiation of B-Lymphocytes (Neipel,
1997a). Whether or not KSV-UNG plays a role in viral genome maintenance or any
pathology associated with the virus remains unknown.

29

1.15 The Function of Viral Uracil DNA Glycosylase
Herpes Viruses are a family of double stranded DNA viruses with large genomes of
approximately 200kb in length (Amon and Farrell, 2005). The genomes of mammalian
herpes viruses contain a uracil DNA glycosylase that shows strong homology to mammalian
UNG2 (Geoui, 2007). Other large double stranded DNA genome viruses families like
poxivirdae viruses such as vaccinia virus and lumpy skin disease virus also carry a copy of
uracil DNA glycosylase (Millns, 1994), (Tulman, 2001). The structure of herpes virus UNG
contains four motifs directly involved with coordinating reactants that are identical to
mammalian UNG2 suggesting there is a highly conserved catalytic mechanism used by all
of these proteins (Fig. 6) (Geoui, 2007). There are two major structural differences between
herpes virus UNGs and their host homologs; most viral UNGs lack the N-terminal domain
that contains regulatory phosphorylation sites and RPA and PCNA interacting motifs that are
thought to help recruit mammalian UNG2 to the site of DNA replication, suggesting viral
UNG may not be recruited to the mammalian replication fork (Hagen, 2008). Herpes virus
UNGs have a seven amino acid insert near the minor groove interacting motif known as the
leucine loop (Fig. 7) that does play a role in contacting the minor groove of DNA, however
this insertion does not seem to significantly effect the activity of the enzyme and its function,
if any, remains unresolved (Geoui, 2007). While the role of many viral UNG during infection
is unclear it has been shown that HSV-1 UNG and simian varicella virus UNG are needed
for these viruses to efficiently infect and replicate in neurons in vivo, suggested that these
UNGs are needed to maintain the integrity of the viral genome during the replication process
(Pyles and Thompson, 1994), (Ward, 2009). Intriguingly host UNG been shown to act on the
genome of the human retrovirus hepatitis B and counteract the antiviral effects of
APOBEC3G (Kitamura, 2013).
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Figure 6
Crystal Structure of Epstein-Barr Virus Uracil DNA Glycosylase
A space-filling model of Epstein Barr UNG facing the catalytic pocket, two highly conserved
residues essential for catalysis, Aspartic Acid-91 in the water activating loop (water molecule
shown in black and blue), and Histidine -213 in the DNA backbone interacting loop, are
highlighted in yellow. These residues are analogous to Aspartic Acid-154 and Histidin-277 in
human UNG (Geoui, 2007).
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Figure 7
Alignment of Human, Mouse, and Gamma Herpes Virus UNG Amino Acid Sequences
Alignment of mouse herpes virus 68 (MHV68) UNG, Kaposi sarcoma associated herpes
virus (KSV) UNG, Epstein Barr (EBV) UNG, mouse UNG2 and Human UNG2. Small
hydrophobic amino acids are shown in red, acidic amino acids in blue, basic in magenta,
and hydroxyl sulfhydryl and amine shown in green. Bars above the sequence indicate
conserved secondary structures. Black boxed regions indicate regions conserved domains
involved in catalysis. Blue box indicates the PCNA interacting motif, the purple box indicates
the RPA interacting motif. (Obtained from clustal Omega).
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A recently published report showed that MHV68, a key model of mammalian herpes
virus infection in vivo, needs viral UNG in order to replicate effectively during infection and
establish latency in mice. This study is the first to demonstrate that MHV-UNG is capable of
complementing Ung-/- mouse B-cells, the main host cell type during latency. Using an in
vitro class switch recombination assay they showed that Ung-/- B-cells expressing mUNG or
MHV-UNG are capable of switching to IgG1 while Ung-/- B-cells expressing empty vector
control are not, demonstrating that viral UNG is capable of participating in the CSR process
at the immunoglobulin locus (Minkah, 2015). They then created a mutant MHV68 virus
(ΔUNG) incapable of expressing UNG by inserting a stop codon in the UNG open reading
frame. Using this ΔUNG virus they show that viral UNG is needed for efficient viral genome
replication in vitro. When immortalized 3T3 cells or primary mouse embryonic fibroblasts are
infected with either wt MHV or ΔUNG-MHV virus in a single step plaque assay the ΔUNGMHV expressing cells show a significantly lower number of plaque forming units. However
both wt MHV both the ΔUNG-MHV infected cells both express viral proteins at similar levels,
suggesting a defect in viral gene transcription or expression, is not responsible for the
impaired ability of virus to replicate (Minkah, 2015). Using an in vitro biochemical assay they
showed that lysates from MHV infected fibroblasts are capable of removing uracil from the
middle of a 19 base pair long substrate. While lysates from cells expressing ΔUNG-MHV did
not show significantly different enzymatic activity compared to the uninfected control
(Minkah, 2015). Significantly they show that viral UNG is essential for MHV replication
during the initial infection in the lungs of mice. Mice infected intranasally with ΔUNG-MHV
showed significantly lower viral titers compared to MHV infected when infected lungs were
homogenized and tittered by plaque assay, suggesting an essential role for viral UNG during
the early stages of mucosal infection (Minkah, 2015). It was also demonstrated that the loss
of MHV-UNG delays the establishment of latency in the spleen of mice, as well as the ability
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of infected splenic cells to reactivate (Minkah, 2015). However they go on to show that
infecting mice with a higher dose of ΔUNG-MHV can partially overcome the defects in
latency establishment and reactivation. Interestingly when mice are infected via
intraperitoneal inoculation and tested for latency establishment and splenocyte reactivation
ΔUNG-MHV infected mice show no significant difference from MHV infected mice (Minkah,
2015). When they examined the effect of viral UNG in other host cell types such as
peritoneal exudate macrophages they found that loss of MHV-UNG had no effect on the
ability of the MHV virus to establish latency or undergo reactivation (Minkah, 2015). They
then showed using a biochemical assay that lysates from MHV infected tissue such as
spleen, and peritoneal exudate cells, retain their UNGase activity, suggesting the active
expression of viral UNG protein in those cell types (Minkah, 2015).
It is however still unknown if herpes virus UNGs play any sort of role in counteracting
intracellular antiviral responses. While UNG is not essential for viability in mammals it plays
an important role in the antibody diversification process in B-cells, one of the major host cell
types these viruses infect (Nilsen, 2000), (Shen, 2006). While EBV infection has been
shown to be associated with autoimmune disorders, suggesting it may play a role in
autoantibody formation (Draborg, 2013). It is not yet known if viral UNGs are capable of
acting on the host genome in any way to enhance or interfere with normal host UNG
processes, or suppress the host immune response to the infection.
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Chapter 2 - Rationale and Hypothesis

2.1 The Role of AID Phosphorylation
We hypothesized that novel phosphorylation sites in AID exist in B-cells that are
important in regulating AID function, and that novel phospho-AID binding proteins interact
with AID to regulate its function. To detect the presence of novel phosphorylation on AID we
developed phospho-specific antibodies to detect p-T150-AID or p-Y184-AID. We predicted
that these phosphorylation events would be detectable using phospho-specific antibodies,
however did not know the conditions needed to induce a detectable level of AID
phosphorylation at these sites. To address this we tested for the presence of these
phosphorylation events in mouse B-cells and 3T3 cells and flag B-cells, and use small
molecule inhibitors in order to understand the signaling pathways that influence AID
phosphorylation. We also treated AID expressing cells with the tyrosine phosphatase
inhibitor NaVO4 in order to produce a robust level of p-Y184-AID that could be detected
using our p-Y184-AID specific antibody. We predicted that these novel AID phosphorylation
sites may be involved with regulating the CSR process. To test this we created nonphosphorylatable mutants of AID to evaluate the effect of AID phosphorylation in CSR in
vitro. We then set up a screen for potential phospho-AID binding partners using a phosphobinding protein domain array. This led us to the prediction that AID might have phosphospecific binding partners that regulate its function. We then cloned these genes into
plasmids to use in later experiments.

2.2 The Involvement of γ Herpes Virus UNG in Antibody Diversification Processes
We hypothesized that Uracil DNA Glycosylases from γ herpes viruses are capable of
processing uracils in the host genome, and by doing so may interfere with AID initiated
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mutagenic events in mammalian B-cells. We tested for the ability of viral UNG to influence
AID mediated mutagenic events such as Class Switch Recombination, Somatic
Hypermutation, Non-Ig locus somatic mutations, and reciprocal translocations. To determine
the effect of viral UNG on AID driven SHM in vitro. We predicted that viral UNG is capable of
acting on AID induced uracils in the mammalian genome. To test this we used a fibroblast
indicator cell line, 3T3-NTZ that express a single GFP copy with a premature STOP codon.
We co-expressed viral UNG and AID in these cells to determine the direct effect of viral
UNG on AID hypermutation. Mutation rates were measured by the reversion rate of the GFP
stop that results in GFP expression. We predicted that viral UNG might be capable of acting
on the host genome B-cells, participating in the CSR process. To determine if viral UNG can
participate in the CSR process we transduced Ung-/- mouse B-cells in vitro with viral UNGs,
and stimulated CSR in the cells. We also predicted that viral UNG may interfere with the
function of host UNG in the CSR process. To test this we transduced naïve B cells from wt
mice with a retrovirus expressing viral UNG and stimulated CSR in vitro. We predicted that
the presence of viral UNG in the CSR process may also lead to an increase of decrease in
off target genomic damage cause by AID. To test this we set up an assay to determine if
viral UNG expression affected translocation rate. We transduced naïve B-cells from mice
with viral UNG and measured translocation frequency using a PCR/Southern blot assay that
selectively amplifies c-myc to IgH chromosome fusions. Reciprocal translocations were
detected and confirmed with southern probes specific to regions of c-myc and IgH within the
amplified region.
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Chapter 3 - The Detection and Effect of AID Phosphorylation
3.1 Class Switch Recombination Assay Characterization and Optimization
Naïve primary mouse B-cells can be stimulated to switch isotypes from IgM to IgG1
in vitro by treating the cells with Lipopolysaccharide (LPS) and Interleukin-4 (IL-4). LPS
activates the TLR-4 receptor, which triggers the expression of AID, while IL-4 receptor
stimulation initiates targeting of AID to the Sµ and Sγ1 switch regions to initiate the CSR
process. There are however many variable that can affect the ability of B-cells to switch in
vitro such as the lot of serum used and the density at which the cells are plated. In order to
determine the affect cell plating density on CSR primary mouse B-cells were plated and
maintained at varying densities in a six well plate in 2ml of B-cell media with LPS and IL-4.
B-cells were plated at 3M, 2M, 1M, 500K or 250K cells per ml. The cells were counted using
a hemocytometer daily, cells were removed from wells and replaced with new B-cell media
to maintain the wells at their given cell density. After three days of in vitro stimulation cells
were stained with an anti-IgG antibody and analyzed by FACS to measure the percentage of
cells switched to IgG1 (Fig. 8). We observed that the B-cells maintained at a lower cell
density over three days have an increased percentage of cell switched IgG1. 6.73% of cells
plated at 3M cells per ml switched to IgG1 while 24.7% of cells plated at 250K per ml
switched to IgG1 (Fig. 8). For all future switch assays cells were maintained at a density of
500K per ml to ensure both a robust percentage of cells switch (21.5% after 3 days), as well
as ensuring at least 2M cells per well are present.
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Figure 8
Plating Density Effects Switch to IgG1 in Primary Mouse B-cells.
Primary mouse B-cells are maintained at different densities show difference in switch after
three days in vitro, percent switch to IgG shown in the upper left quadrant. wt B-cells
maintain at lower cells densities have increased switch levels, Aid-/- B-cells maintained at
500K cells per ml do not switch. All cells were plated in 6 well plates with 2ml of B-cell media
with 10 µg/ul IL-4 and 25µg/ml LPS.

38

While LPS and IL-4 stimulation are essential for switch, other growth factors present
in FBS are also capable of having a significant impact on the ability of B-cells to switch in
vitro. In order to determine which lot of serum consistently allows for the highest percentage
of cells to switch, we tested several lots from different companies. Primary mouse B-cells
were plated at a density of 500K per ml in a six well plate, along with LPS and IL-4 in B-cell
media containing 10% FBS. After 3 days in vitro cells were stained with an anti-IgG1
antibody and measured by FACS (Fig. 9). While all of the sera tested caused at least 20%
of cells to switch, fetal bovine serum from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO.
Catalog# F6178) stimulated the highest percent switch at 26%. This serum was used for all
future experiments.
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Figure 9
The Lot of Serum used During the CSR Assay can Effect Switch Efficiency
Fetal Bovine Serum from at least 4 different suppliers was tested for its ability to effect CSR
efficiency. The cells were maintained at 500K per ml in B-cell media with 10%FBS +IL-4
+LPS and measured by FACS after 3 days in vitro. As a negative control, Aid-/- and wt Bcells with no IL-4 do not undergo CSR. Percent switch to IgG is show in the lower right quadrant.
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3.2 Chromatin Associated AID is Highly Modified
Previous studies had shown that most AID is localized in the cytosol (McBride,
2004). In order to determine the posttranslational modification state of AID relative to its
subcellular localization a two-dimensional gel analysis and immunoblot was performed. 3T3
were cells infected with virus containing pMX-FLAG-AID. Three days after infection the cells
were lysed on ice with RIPA with NaF and Calyiculin in order to isolate protein lysates while
preserving protein phosphorylation states. Cell lysates were then subjected to sucrose
gradient equilibrium density ultracentrifugation to isolate chromatin-associated proteins.
FLAG-AID was then immuno-precipitated from whole cell lysates and chromatin associated
fraction using anti-FLAG beads. FLAG-AID protein was then eluted off of the bead and run
on an immobilized pH gradient acrylamide gel strip to separate proteins by charge then run
orthogonally on a SDS-PAGE gel and to separate proteins by size. The proteins are then
transferred to a nitrocellulose membrane and immunoblotted for AID (Fig. 10). The results
indicate that while FLAG-AID from whole cell lysate and from the chromatin associated
fraction have the same molecular mass, there is a large differential in the range of isoelectric
points between species in the whole cell extract and species in the chromatin associated
fraction. Overall FLAG-AID from the chromatin-associated fraction had a more negative
isoelectric point than the whole cell extract, which suggests that chromatin associated AID is
highly phosphorylated. Given these results posttranslational modification is likely a
mechanism in regulating the functional activity of AID at the chromatin level.
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Figure 10
Chromatin Associated AID is More Negatively Charged than Whole Cell AID
Flag-AID isolated from the chromatin associated fraction reaches its isoelectric point at a
lower pH than, Flag-AID isolated from whole cell extracts, indicating that it is more
negatively charged, most likely do to protein phosphorylation. 3T3 MEF cells transduced
with Flag-AID, and lysed with RIPA buffer after 3 days in vitro. Chromatin was isolated by
equilibrium density centrifugation from Flag-AID expressing cell lysates. Flag-AID was then
immuno-precipitated with anti-Flag beads from either whole cell extract or the isolated
chromatin fraction. Immuno-precipitated lysates were then separated on a 3-10 immobilized
pH gradient, then separated by molecular weight by SDS-PAGE. Proteins were then
transferred to a membrane and blotted with an anti-AID antibody (courtesy of Sean
Hensley).
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3.3 Generation of Phospho-Specific Antibodies
In order to detect p-Y184 AID and p-T150 AID we developed two poly-clonal mouse
antibodies that specifically recognizes p-Y184 AID or p-T150 AID. To test the sensitivity and
the specificity of these antibodies for their specific epitope peptides containing p-Y184 AID,
p-T150 AID, or recombinant AID were serially diluted and spotted onto an activated
nitrocellulose membrane. The membranes were then blocked and incubated with either the
anti p-Y184 or the anti p-T150 antibody for one hour, washed three times, incubated with a
anti mouse-HRP secondary and developed with ECL. The results showed that each
respective anti-phospho-AID antibody specifically recognized its intended epitope (Fig. 11).
The anti p-Y184 AID antibody was able to detect the p-Y184 substrate at a concentration of
about 2 x 10-2 µg, while the anti p-T150 AID antibody was able to specifically detect the pT150 AID peptide at a concentration of 2 X10-8 µg.
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Figure 11
Anti p-Y184 AID is Specific for Phosphorylated AID Peptide
AID peptides containing p-Y184, p-T150 or un-phosphorylated recombinant AID (rAID) were
serially diluted from 2µg to 2 X 10-12 µg spotted onto a nitrocellulose membrane, blocked
with either 5% BSA or 5% Milk in TBST, and probed with anti p-184 AID antibody at a
dilution of 1:5000. The anti p-184 AID antibody specifically recognizes p-Y184 AID peptide
at concentrations approximately 2 X 10-2 µg in 5% milk. The antibody does not recognize the
p-T150 peptide or the un-phosphorylated rAID at any concentration.
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While the sensitivity and specificity of the phospho-specific antibodies has been
demonstrated, it is not known if AID is indeed phosphorylated at these sites cells. In order to
test this primary mouse B-cells from Aid-/- mice were isolated, plated, and retroviraly
transfected with either FLAG-AID or FLAG-AIDY184F. The cells were stimulated with LPS and
IL-4 for three days. To induce tyrosine phosphorylation cells were exposed to NaVO4 for
thirty minutes before the cells are pelted and lysed with RIPA. Western blots of the lysates
where then performed using the anti p-Y184 AID antibody (Fig. 12) showing that the p-Y184
AID species is detectable after NaVO4 treatment, but not in the FLAG-AIDY184F expressing
cells. This data demonstrates that the p-Y184 AID species does exist in mouse B-cells, and
therefore tyrosine kinase pathways that are capable of targeting and phosphorylating AID in
B-cells.
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Figure 12
The Anti 184-Antibody Specifically Recognizes p-Y184 AID Isolated from Mouse
B-cells
Western blot showing the presence of p-T184 AID in B-cells. Primary mouse splenocytes
isolated from Aid-/- mice were transduced with flag-AID or flag-AIDY184F, and simulated in
vitro with LPS and IL-4. Transduced or uninfected cells were treated with NaVO4 for 30
minutes to induce tyrosine phosphorylation prior to lysis, immuno-precipitation and
immunoblotting with the anti p-Y184 AID antibody.
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3.4 The Effect of AID Phosphorylation on Class Switch Recombination
The effect of AID phosphorylation on CSR has been studied in detail for
phosphorylation sites such as serine 38 and serine 3, however there are other putative
phosphorylation sites on AID that have yet to be thoroughly characterized. In order to
understand the influence that phosphorylation of Y184, T150, T158, and S169 may have on
CSR isolated Aid-/- B-cells were retroviraly transduced with FALG-AID-Y184F, FLAGT150A, FLAG-T158A and FLAG-S169A and stimulated to switch with LPS and IL-4. FACS
analysis of the AID mutant infected cells showed that the T158A mutation over all showed
little effect on switch, the S169A and the Y184F mutations reduced switch by 30 - 60%,
while the T150A mutation caused almost complete loss of the ability of cells to switch (Fig.
13). We can conclude from these findings that phosphorylation of T150, S169 and Y184 of
AID may be necessary steps in the CSR pathway in order to obtain maximum switching
efficiency. T150 of AID in particular seems to be an important residue for the CSR process
and further study is needed to understand its role in this process in vitro and in vivo. Our
results indicate the AIDY184F mutation reduces switch slightly, indicating that tyrosine kinase
pathways may be a distinctive regulatory mechanism for AID regulation.
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Figure 13
Class Switch Recombination Efficiency is Effected by AID Phosphorylation (A) wt Bcells stimulated with LPS + IL-4 in vitro switch from IgM to IgG which can be measured by
FACS. Aid-/- B-cells do not undergo switch in vitro when stimulated with LPS + IL-4. Aid-/B-cells can be transduced with virus containing pMX-AID. AID expression from pMX allows
Aid-/- B-cells to switch when stimulated with LPS + IL-4 in vitro; orange box. The
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transduction efficiency can be measured by the expression of the IRES driven GFP; green
box (B) Aid-/- B-cells are infected with virus containing AID, or AID with point mutations
preventing phosphorylation at T150, T158, S169, or Y184. FACS plots showing the effect of
phosphorylation on switch, wt AID shows the greatest ability to switch, while all of the
nonphosphorylatable mutant forms of AID show reduced switch.

3.5 Putative Phospho-AID Interacting Proteins
In order to discover potential phospho-AID binding proteins we employed phosphoprotein binding array that contained immobilized SH2 phospho-tyrosine binding domains.
We probed this array with a fluorochrome tagged peptide of the AID c-terminus containing
phosphorylated Y184. If the phospho-peptide binds to the phospho-binding domain it will be
detectable upon fluorescent imaging of the array (Fig. 14). The results revealed four
potential AID-p-Y184 binding partners two tyrosine kinases FYN and ABL2, a guanine
nucleotide exchange factor VAV2, and an adaptor protein SH3BP2 that also contains an
SH2 domain. A previous report showed that Sh3bp2 knock out mice showed unexpected Bcell phenotype that included a defect in CSR (Chen, 2007). Due to this fact we decided to
focus on SH3BP2 to understand the potential roles phospho-binding proteins may play in
regulating AID function.
To test for the expression of SH3BP2 in mouse B-cells we isolated and purified
mRNA, then used oligo-dT and reverse transcriptase to generate a cDNA library of genes
actively transcribed by mouse B-cell under LPS and IL-4 stimulated conditions. Using
specific primers we were able to amplify SH3BP2 from this cDNA library (Fig. 15),
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demonstrating it is actively transcribed in mouse B-cell. We purified these PCR products and
ligated them into the pMX-expression vector to be able to express SH3BP2 protein in future
experiments.
In order to detect SH3BP2 protein in cells we purchased two separate anti-SH3BP2
polyclonal goat antibodies Clone C-19 and N-18 (Sanata Cruz Bio, Dallas, TX). We used
these antibodies to perform western blots on protein lysates from LPS and IL-4 stimulated
mouse B-cells, HEK cells, and HEK cells transfected with pMX-SH3BP2 (Fig. 16). Of the
three groups tested we were only able to detect SH3BP2 protein in the pMX-SH3BP2 group,
and although SH3BP2 protein was detectable using both antibodies the N-18 clone proved
to be significantly more sensitive than the C-19 clone. While the mRNA of SH3BP2 was
detectable in mouse B-cells we were unable to identify protein from them using these
antibodies. These results suggest that SH3BP2 may be expressed in B-cells but at a level
too low to be detected, at least with the current antibodies available on the market.
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Figure 14
Phospho-AID Peptides Interact with Phospho-Binding Protein Domains
An AID peptide containing phosphorylated Y184 interacts with SH2 domains from four
different proteins. An array of protein phospho-binding domains were immobilized on a
nitrocellulose coated slide. Arrays are then probed with Cy3 tagged phospho-AID peptides
and washed. Protein domains that strongly bind phospho-AID peptides are identified by Cy3
fluorescence. (Courtesy of the Bedford lab)
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Figure 15
Phospho-Tyrosine Binding Protein SH3BP2 is Expressed in wt Mouse B-cells
Ethidium-bromide gel staining showing SH3BP2 PCR products amplified from mouse B-cell
cDNA. cDNA from mouse B-cells was isolated using oligo-dT primers to amplify mRNA.
Specific primers for SH3BP2 were able amplify the 1677bp gene at cDNA concentrations
from 900ng to 100ng. As a positive control 594bp AID was amplified from the same cDNA
with AID specific primers. SH3BP2 gel bands were then isolated and cloned into vectors for
later use.
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Figure 16
SH3BP2 can be Detected from Cell Lysate by Western Blot
Western blots testing two different anti-SH3BP2 antibodies. SH3BP2 can be detected using
the N-18 antibody in cells transfected to over express SH3BP2. Bands were not visible in
extracts from wt B-cells or untransduced HEK cells, suggesting that these antibodies are not
able to detect SH3BP2 protein at endogenous levels.
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3.6 Differential Regulation of The PI3 Kinase Pathway on AID-S38 Phosphorylation
In order to better understand the signal transduction pathways that lead to or inhibit
AID phosphorylation we treated AID expressing cells with a number of different small
molecule inhibitors. We discovered that a small molecule inhibitor of the PI3Kinase pathway
LY29004 was able to cause an increase in the amount of AID-S38 phosphorylation when
3T3 cells expressing FLAG-AID were exposed to the chemical for several minutes (Fig. 17).
Intrigued by these results, we repeated the same experiment using LPS and IL-4 stimulated
mouse B-cell, however exposure to LY29004 had no effect on FLAG-AID S38
phosphorylation, suggesting a difference in the signaling pathways that regulate AID-S38
phosphorylation between these two cell types.
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Figure 17
The PI3Kinase Inhibitor LY29004 Stimulates AID S38 Phosphorylation in 3T3 Cells but
not B-cells
3T3 cells are transfected with pMX-FLAG-AID, or left untransfected as a control. The
PI3Kinase inhibitor LY29004 was applied for varying lengths of time. The cells were then
lysed and immuno-precipitated using anti-FLAG beads, then eluted and western blotted with
an anti p38-AID antibody. Cells showed an increase in S38 phosphorylation that was time
dependent. However when the experiment was repeated with FLAG-AID expressing B-cells
LY29004 treatment produced no effect on AID S38 phosphorylation. Both membranes were
then stripped and reprobed with an anti-AID antibody to ensure equal loading.
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3.7 Chapter 3 Summary
While the in vitro CSR assay is a powerful tool to study the isotype class switching
process, our initial characterization experiments demonstrate the sensitivity of this system to
variables such as serum lot, and cell plating density. These factors are capable of having a
significant influence on the CSR process in vitro, and therefore need to be controlled in
order to ensure consistent experimental results. Using a two-dimensional gel analysis we
found that chromatin associated AID has a significantly lower isoelectric point than AID
isolated from whole cell extracts, implying that chromatin associated AID is heavily
phosphorylated. These results suggest that proper phosphorylation of AID is necessary
before it can associate with genomic DNA. There are several phosphorylation sites on AID
whose function is unknown. In order to determine if these AID phosphorylation sites regulate
the CSR process we tested the effect of their absence in the in vitro CSR process. We found
that three of these site mutations T150A, S169A, Y184F reduced the ability of cells to
switch, suggesting phosphorylation at these sites is needed for optimum CSR efficiency.
Where as the T158A mutation had no measurable effect on switch, implying it plays no role
in the regulation of CSR. We also developed antibodies that specifically recognize
p-T150-AID or p-Y184-AID, and show that it is possible to detect p-Y184-AID in mouse
B-cells after treatment with tyrosine phosphatase inhibitor NaVO4. However the signaling
pathways that lead to AID phosphorylation at these sites remain unresolved. We also used a
protein domain array to screen for potential phospho-AID specific binding partners, a
completely untouched area in the AID field. The screen revealed four potential phospho-AID
interacting proteins, some of which are known to be important in other B-cell pathways. We
were able to show that the adaptor protein SH3BP2 is actively expressed in mouse B-cells,
although not at levels high enough to be detected by western blot with commercially
available antibodies. Our data demonstrate a regulatory role for multiple phosphorylation
sites in the CSR process, and that there may be factors that interact with AID in a

56

phosphorylation specific manner. While these results are intriguing, further research is
needed to understand the significance of these findings, and how they influence B-cell
biology.
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Chapter 4 - The Effect of Viral Uracil DNA Glycosylases on Antibody Diversification
Processes in Mammalian B-cells

4.1 Viral UNGs are Able to Partially Restore Isotype Class Switch Recombination in
Ung-/- Mice
Detection and removal of uracil in the switch region DNA is a crucial step in the CSR
process, therefore Ung-/- mice are almost completely deficient in their ability to switch
isotypes. B-cells are known to be the main host cell type for gamma herpes viruses, it was
however unknown if their viral UNGs are able to act on the host cell genome and participate
in antibody diversification processes such as CSR that rely heavily on the host UNG. In
order to determine if viral UNGs are able to participate in the CSR process, Ung-/- B-cells
were isolated and transduced with retrovirus containing pMX-MHV68-UNG, pMX-EBV-UNG,
pMX-KSV-UNG or an empty pMX control vector. The infected B-cells were then cultured in
the presence of LPS and IL-4 for four days, then stained with an anti-IgG-APC antibody and
analyzed by FACS. To our surprise expressing any of the viral UNGs in the Ung-/- B-cells
was able to induce approximately 20% of the cells to switch to IgG1 (Fig. 18), in comparison
to the empty vector control which had negligible percentage of cells switch. We can
conclude from these experiments that viral UNGs are capable of acting on the host genome
in B-cells and are able to participate in the class switch recombination process at the Ig
locus.
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Figure 18
Expression of Viral UNG in Ung-/- B-cells Provides Partial Compensation During CSR
in vitro
UNG is introduced to the cells by retroviral infection, after 4 days of LPS and IL-4 stimulation
in vitro, the cells are analyzed for UNG-IRES-GFP expression and switch to IgG1 by FACS.
(A) Representative FACS plots of Ung-/- cells expressing viral UNG. Ung-/B-cells expressing MHV UNG, EBV UNG or KSV UNG are able to switch to IgG1 at a level
significantly higher than cells expressing the vector control or the truncated protein MHVSTOP UNG. The percent of infected cells that have switched to IgG1 are shown in the upper
right corner. (B) Average switch of Ung-/- cells expressing viral UNG to IgG1, averaged of
three separate experiments. p < 0.001 for viral UNG expressing cells compared to the vector
control.
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4.2 Viral UNGs Suppress Class Switch Recombination when Expressed in wt Mouse
B-cells
After discovering that viral UNGs are capable of participating in the CSR process in
Ung-/- cells we wanted to more accurately model the gamma herpes virus infection. To
model this we purified and infected wt B-cells and transduced them with retrovirus
containing pMX-MHV68-UNG, pMX-EBV-UNG, pMX-KSV-UNG, empty pMX control vector,
or pMX-MHV-STOP UNG a nonfunctional truncated form of MHV-UNG. After four days of in
vitro stimulation with LPS and IL-4, the percentage of cells switched to IgG1 was measured
by FACS analysis. To our surprise all the expression of full length viral UNGs suppressed
the ability of wt B-cells to switch isotypes by approximately 50% compared to the empty
vector control (Fig. 19). We can conclude from these results that the expression of viral UNG
in wt B-cells is somehow interfering with the molecular processes involved in CSR. Given
these surprising results we developed two models in an attempt to explain the effects of viral
UNG in the CSR process (Fig. 20). In the first model, referred to as the scaffolding model,
we propose that viral UNG competes with endogenous host UNG for binding partners
involved in the CSR process, thereby reducing the number of fully functional UNG
complexes and the efficiency of the CSR process (Fig. 20). The second model, the
enhanced clearance of uracil model, proposes that with the additional expression of viral
UNG there is too much UNG catalytic activity, and this excess UNG activity does not allow
enough uracils to accumulate at the switch regions to lead to a double strand break (Fig.
20).
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Figure 19
Expression of Viral UNG in wt mouse B-cells Suppresses CSR in vitro
(A) Representative FACS plots of wt mouse B-cells expressing viral UNG. After 4 days of
LPS and IL-4 stimulation in vitro B-cells expressing MHV-UNG, EBV-UNG or KSV-UNG
show significantly reduced ability to switch to IgG1. The percent of infected cells that have
switched to IgG1 are shown in the upper right corner. (B) Average switch of wt B-cells
expressing viral UNG to IgG1, averaged of three separate experiments. p < 0.001 for viral
UNG expressing cells compared to the vector control.
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Figure 20
Two Potential Models to Explain the Ability of Viral UNG to Suppress CSR in wt Bcells.
A) A model for CSR in wt B-cells; AID is targeted to the switch regions where it introduces
uracils on both strands of DNA. UNG then removes these uracils to produce abasic sites
that are then nicked by AP-endonuclease (APE), resulting in a double strand break.
Processing and ligation of the break to another switch region by the NHEJ pathway leads to
CSR. B) The scaffolding model; viral UNG is able to form a partially functional complex with
UNG associated cofactors compensate for the loss of mUNG when expressed in Ung-/- Bcells. However in when viral UNG is expressed in wt B-cells it competes for binding factors
(represented by green circles and orange triangles) with mUNG leading to less efficient
removal of uracils, limiting downstream processes and reducing ability of cells to complete
the CSR process. C) The enhanced clearance of uracil model; in wt B-cells when viral UNG
is expressed with endogenous UNG, the over abundance of UNG does not allow AID
induced uracils to accumulate to the critical level needed to cause a double strand break;
the abundance of UNG removes and repairs uracils in a high fidelity manner before
downstream CSR mechanisms can be initiated.
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4.3 UNG Catalytic Activity is Nonessential for Suppressing CSR in wt Mouse B-cell
To determine the mechanism of action of viral UNG interference in the CSR process,
we produced two UNG mutants, a catalytically inactive form of mUNG, and a catalytically
inactive form of MHV-UNG. Previous studies had shown that it was necessary to mutate at
least two residues essential for catalysis in order to completely eliminate catalytic activity
from mouse UNG (Di Noia, 2007). We replicated two of these mutations in mouse UNG, one
in the water activating loop (141VVILGQDPYH151), and one in the DNA backbone interacting
leucine loop (270HPSPL274) using site directed mutagenesis (Fig. 21). Although it had never
been attempted, the identical sequence conservation of catalytic motifs in MHV-UNG
allowed us to make identical point mutations by site directed mutagenesis.
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Figure 21
UNG Catalytic Mutants are Generated by Site Directed Mutagenesis
Either mUNG or MHV-UNG were excised from pMX by restriction endonucleases. Then was
ligated in to the smaller vector pDUET, and used to transform competent bacteria. Plasmids
then undergo PCR with the site directed primers and high-fidelity pfuTurbo DNA
polymerase. The PCR products are then digested with DpnI in order to remove the
methylated unmutated template DNA. The Digested PCR product is then used transform
competent bacteria, from which individual clones are picked, and purified for plasmid DNA.
The DNA is then sequenced to check for the presence of the mutation. Plasmids containing
the mutation are then subjected to a second round of site directed PCR using the second
set of primers to induce the second mutation. Purified plasmids are then sequenced to test
for the presence of both mutations. Once both mutations are verified by sequencing the
mutated UNG insert is excised and ligated into pMX.
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We then transduced both Ung-/- B-cells and wt B-cells with catalytically inactive
mUNG, catalytically inactive MHV-UNG, mUNG or MHV-UNG and stimulated them for four
days in vitro in the presence of LPS and IL-4 then measured by FACS for switch. We found
that catalytic activity is necessary for either mUNG or MHV-UNG to stimulate class switching
in Ung-/- cells, however both the catalytically active and inactive forms of the proteins are
able to suppress switch in wt B-cells (Fig. 22). These results suggest that viral UNG is
interfering with the endogenous class switch process via a scaffolding mechanism that does
not require UNG catalytic activity.
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Figure 22
UNG Catalytic Activity is Necessary for Ung-/- CSR Compensation But Dispensable
for Suppression of CSR in wt B-Cells
(A) Alignment of the amino acid sequence of mUNG and MHV68-UNG showing the
conservation of the catalytic domain between the host and virus UNG (B) Representative
FACS plots showing the ability of catalytically active UNG to increase switch in Ung-/- Bcells, while catalytic activity of UNG is not necessary for suppression of switch in wt B-cells.
(C) Graphical representation of the average effect on CSR when catalytically active and
inactive UNGs are expressed in Ung-/- (D) or wt mouse B- cells. Average of three separate
experiments (E) Catalytically inactive mUNG and MHV68 UNG are stably translated in
Ung-/- cells. Anti-FLAG WB of lysates from cells expressing mUNG-FLAG, MHV-FLAG,
mUNG-CAT.MUT-FLAG or MHV-CAT. MUT-FLAG.

69

4.4 Viral UNG Suppresses IgH-cMYC Translocations When Expressed in Mouse
B-cells
There is as large body of evidence linking Epstein-Barr infection to the development
of Burkitt’s lympoma(Young and Rickinson, 2004). It has also been established that the
molecular events that initiate CSR are also responsible for the formation of the IgH-cMYC
translocation, the hallmark of Burkitt’s lymphoma (Ramiro, 2006). Upon the discovery that
viral UNGs interfere with the CSR process we wanted to determine if IgH-cMYC
translocation rates were also affected by viral UNGs. In order to test this we infected wt
B-cells with retrovirus containing either pMX MHV-UNG or an empty pMX control vector.
The cells were stimulated for four days in vitro with LPS and IL-4 then analyzed by FACS.
GFP positive cells expressing the pMX vector were sorted and collected (Fig. 23). Genomic
DNA from the GFP positive cells collected was amplified by PCR using IgG and cMYC
specific primers which amplify IgH-cMYC reciprocal translocations. The PCR products were
then run on and agarose gel and transferred to a nylon membrane for southern blotting. The
membranes were then probed with probes specific for IgH or cMYC, and spots positive for
both IgH and cMYC probes were counted as reciprocal translocations (Fig. 24). The
frequency of translocations in wt B-cells infected with pMX MHV-UNG was reduced by
approximately 60% compared to the empty pMX control infected cells (Fig. 24)(Table 4-1).
From these results we conclude that the expression of viral UNGs in B-cells may in fact
reduce the probability of oncogenic translocations, therefore loss of viral UNG expression
may be a necessary step in the transformation of gamma herpes virus infected cells.
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Figure 23
Experimental Design for the IgH-cMYC Translocation Assay
Primary mouse B-cells isolated and plated at a density of 1 X 106 cells per ml for 12 hours.
The cells are then re-plated into 6 well plates at a density of 500K per ml and infected with
either pMX MHV-UNG virus or pMX empty vector control virus. The cells are kept at 500K
per ml until 60 hours after infection at which point they are sorted for GFP expression (green
boxes). After sorting genomic DNA is isolated from the GFP positive cells and long range
PCR is performed using cMYC and IgH specific primers using 500ng of DNA per reaction.
The PCR products are then run on a 1% agarose gel, imaged using ethidium bromide then
transferred to a nylon membrane and probed for cMYC and IgH.
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Figure 24
MHV-UNG Expression Decreases IgH-Myc Translocations in wt mouse B-Cells
(A) Ethidium bromide staining, anti-cMyc and anti IgH Southern blots of translocation PCR
products from vector control infected, or MHV-UNG infected wt B-cells. (B) FACS analysis of
cells sorted for DNA; MHV-UNG expression suppresses switch to IgG1. (C) Myc-IgG
translocation rate per million cells, MHV-UNG expression significantly reduces translocation
frequency compared to vector control. Average of four independent experiments. p =
0.0037 Fischers Exact test.
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Table 2A
IgH-cMYC Translocation Data from Four Independent Experiments
Lanes with
Replicate

Gel lanes

Cell Number Reciprocal

Translocations per lane

Translocations
1 Vector

12

1,200,000

2

0.166666667

2 Vector

8

800,000

8

1

3 Vector

16

1,600,000

4

0.25

4 Vector

48

4,800,000

10

0.208333333

84

8,400,000

29

0.34523

1 MHV

12

1,200,000

1

0.08333

2 MHV

8

800,000

1

0.08333

3 MHV

16

1,600,000

0

0

4 MHV

48

4,800,000

10

0.2083333

84

8,400,000

12

0.142857

Vector
Total

MHV
Total
Table 2B Statistical Analysis of Translocation Data
Translocation
Vector 29

No Translocation
55

MHV

12

72

Total

41

127

Fischer’s Exact Test P=0.0037
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4.5 Viral UNGs Suppress AID Induced Reversion Mutation in NTZ-3T3 Reporter Cell
Line
The NTZ-3T3 reporter cell line system contains a GFP exon driven by a CMV
promoter, however the GFP contains a premature STOP codon that prevents protein
translation. If the cells are exposed to a mutagen such as AID, a small number of cells will
be mutated at the STOP codon leading to GFP expression (Fig. 25). The percentage of cells
that revert the GFP STOP codon can then be measured by FACS analysis. This system has
been utilized by other groups to study the effect of mutations on AID function, however we
used the NTZ-3T3 system in order to test for the ability of viral UNGs to suppress AID
mediated mutations in the host genome (McBride, 2006).

Figure 25
Error Prone Repair at the GFP-STOP Codon in NTZ-3T3 Cells is Needed to Initiate GFP
Transcription After AID Deamination
After expression AID is able to deaminate the cytosine to uracil in the complementary strand
opposite the STOP codon TAG. If the site is left unrepaired DNA polymerase will read the
uracil as a thymine leading to adenine being place in opposite strand giving a codon of TAA,
which is still a STOP codon. If UNG recognizes the U:G mismatch, removes the base and
triggers the high fidelity base excision repair pathway, the uracil is returned to a cytosine
maintaining the STOP codon. However if the U:G miss match is repaired in such a way that
replaces the uracil with an adenine or a guanine, then transcription of GFP will occur driven
by the CMV promoter.
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To test this we infected NTZ-3T3 cells with virus containing pMX-ΔGFP vector
containing viral UNG. After 48 hours the cells are subjected to puromycin selection, the cells
were then placed in tetracycline free media, and then infected with virus containing pMX
AID-BFP or pMX AID-mCherry. The day of AID infection is considered to be the start (day
zero) of the assay (Fig. 26). The cells were kept at a low density and passaged at regular
intervals, during the passaging cells are taken and measured by FACS analysis at regular
intervals to measure the rate of GFP reversion. The results show that when expressed with
AID all of the viral UNGs tested were able to suppress AID induced reversion mutations in
NTZ-3T3 cells at comparable efficiency (Fig. 29). Over the course of the assay cells
expressing AID alone show a steady increase in reversion percentage, while cells
expressing any of the viral UNGs with AID show a significant reduction in the number of
reverted cells (Fig. 27), (Fig. 28). From these results we can conclude that viral UNGs are
fully capable of repairing AID induced deamination mutations in the host genome. Future
sequencing analysis of the GFP gene will reveal if the presence of viral UNG influences the
spectrum of mutations present.
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Figure 26
NTZ-3T3 Experimental Time Line
NTZ-3T3 cells are transduced with retrovirus containing pMX-vUNG, the cells are then
selected for pMX expression for 48 hours using puromycin, then placed in tetracycline free
media. The selected cell are then transduced with pMX AID-BFP or pMX-AID-mCherry
containing retrovirus, which is considered day 0 of the assay. The cell are then passaged
and scanned at regular intervals to test for GFP reversion.
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Figure 27
EBV-UNG and KSV-UNG Suppress AID Induced GFP Reversion Rates in NTZ-3T3
Cells Over Time
NTZ-3T3 cells infected with pMX AID-BFP and pMX EBV-UNG or pMX KSV-UNG were
trypsinized and passaged at regular intervals. Representative FACS plots of cells
expressing pMX-AID BFP and for the presence of GFP+ reverted cells. NTZ cells
expressing pMX AID-BFP show an increase in the percentage of reverted cells from 0.054%
to 0.193% over six day period. Cells expressing pMX EBV-UNG and pMX AID-BFP showed
a reduction in the rate of GFP reversion from 0.007% to 0.014% over a six day period, and
cells expressing pMX AID-BFP with pMX KSV-UNG showed a reduction in the rate of GFP
reversion from 0.003% to 0.03% over the course of six days.
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Figure 28
Expression of Viral UNGs in NTZ-3T3 Cells Suppresses GFP Reversion
(A) Graph of the reversion rates of NTZ-3T3 cells. Cells expressing EBV-UNG, KSV-UNG,
or MHV-UNG showed a significant reduction in GFP reversion frequency compared to AID
only controls. NTZ-3T3 cells were infected with pMX EBV-UNG, pMX KSV-UNG, pMX MHVUNG or empty pMX control and selected using puromycin. After selection cells were infected
with AID-BFP or AID-mCherry, cells were then trypsonized and scanned by FACS at various
time points in order to measure reversion rates. (B) An image of a reverted NTZ-3T3 cells
expressing GFP.
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Figure 29
EBV-UNG, KSV-UNG and MHV-UNG all Suppress AID Induced GFP Reversion in NTZ3T3 Cells
NTZ-3T3 cells infected with pMX AID-BFP and pMX EBV-UNG or pMX KSV-UNG or pMXMHV were trypsinized and measured after 5 days. Representative FACS plots of cells
expressing pMX-AID BFP and for the presence of GFP+ reverted cells. Cells expressing
AID only had a reversion rate of 0.0125% while cells expressing EBV-UNG, KSV-UNG or
MHV-UNG showed reduced reversion percentages. Cells expressing the truncated pMXMHV-STOP showed similar reversion rates to the Empty vector control.
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4.6 Chapter 4 Summary
During the course of our research we discovered a novel virus-host interaction
mechanism. The action of viral UNG on host DNA may be an important mechanism for the
survival and propagation of the herpes virus in host B-cells, as well as having implications
for the development of herpes virus associated B-cell lymphomas. The expression of viral
UNGs in Ung-/- mouse B-cells was able to compensate for host UNG in the CSR process.
However when expressed in wild-type mouse B-cells viral UNGs reduced CSR efficiency,
demonstrating the importance of UNG levels in CSR process. Intriguingly we discovered that
UNG catalytic activity is not necessary for this suppression of CSR efficiency, suggesting a
potential UNG protein-scaffolding mechanism is responsible for this effect. We also
discovered that the action of viral UNG on the host genome can reduce the frequency of
oncogenic translocations and genomic instability, implying that viral UNG maybe playing an
active role in preserving the integrity of the host cell genome. We also measured the ability
of viral UNG to suppress AID generated mutations in the NTZ-3T3 indicator cell line. Later
DNA sequencing analysis of these cells will allow us to determine if viral UNG alters the
spectrum of mutations present in the cells, which may provide potential insight into how error
prone repair of genomic uracils is triggered.
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Chapter 5 - Materials and Methods
5.1 Antibodies and Reagents


Anti-FLAG M2 antibody was used for western blots (Sigma-Aldrich, St. Louis, MO.
Catalog #F3165).



APC-rat anti mouse IgG-APC(BD pharmagen, Franklin Lakes, NJ, Catalog# 560089)
was used for CSR assays.



Anti-FLAG M2 Affinity Agaros Gel Beads (Sigma-Aldrich, St. Louis, MO. Catalog
#A2220).



Lipopolysaccharides (LPS) from Escherichia coli (Sigma-Aldrich, St. Louis, MO.
Catalog #L2630).



Mouse Interleukin-4 (Sigma-Aldrich, St. Louis, MO. Catalog #I1020)



MACS anti-CD43 (Ly-48) MicroBeads (Miltenyi Biotech, San Diago, CA, Catalog#
130-049-801)



Rabbit anti-mAID antibody 30F12 (Cell Signaling Technology, Danvers, MA, Catalog
#4949)



Goat anti-SH3BP2 antibody N-18 (Santa Cruz Bio, Dallas, TX, Catalog # sc-113954)



Goat anti-SH3BP2 antibody C-19 (Santa Cruz Bio, Dallas, TX, Catalog # sc-8897)



Pfu turbo DNA polymerase AD (Agilent technologies, Santa Cruz, CA. Catalog
#600255).



PI3K inhibitor LY294002 (Sigma-Aldrich, St. Louis, MO. Catalog #L9908)
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5.2 Experimental Methods
Primary Splenocyte isolation
Adult mice at least six weeks of age are sacrificed, their spleens are then surgically
removed and placed into a 15ml conical tube containing 5ml of phosphate buffered saline
(PBS) which are then kept on ice. The spleens and PBS are then transferred to a 10cm

filter (Fischer Scientific, Waltham, MA, Catalog# 08-771-2) where they are crushed and
presses through the filter using the plunger from a sterile 5ml syringe (BD pharmagen,
Franklin Lakes, NJ, Catalog# 309647). The filter containing the solid spleen tissue is then
discarded, and the PBS containing the primary splenocytes is transferred to a 15ml conical
tube and spun at 1500RMP for 5min to pellet the cells. The majority of the PBS is aspirated
off of the cell pellet, the conical tube is then raked across a tube rack in order to re-suspend
the splenocyte cell pellet. 1ml of Ammonium-Chloride-Potassium (ACK) red blood cell lysis
buffer is then added to the re-suspended splenocytes and allowed to incubate for 1min at
room temperature. The lysis reaction is then neutralized by adding 10ml of PBS to the tube

separate the freely floating leukocytes from the coagulated cell debris, and placed into a
new 15ml conical tube. The tube is then spun at 2300RPM for 5min in order to pellet the
primary leukocytes. The cells are then re-suspended in 10ml of PBS and counted.

Isolation of naïve CD43- B-cells by magnetic activated cell sorting
Purified primary leukocytes in PBS are spun at 1500PRM for 5min in a conical tube.
The cells are then resuspended at density of in 1 x 107 cells per 900l of PBS, and 100l of
MACS anti-CD43 beads (Miltenyi Biotech, San Diago, CA, Catalog# 130-049-801) are
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added and incubated with the cells on ice for 20min, with occasional mixing to prevent cell
precipitation. For every 1 x 107 cells one MACS-MS column (Miltenyi Biotech, San Diago,
CA, catalog # 130-042-201) is placed on a MACS magnet and stand (Miltenyi Biotech, San
Diago, CA, Catalog# 130-042-108) in a sterile tissue culture hood. The MACS -MS column
is washed with 1ml of cold PBS 1% FBS. To wash the cells 10ml of cold PBS is added to the
tube, and it is spun at 1500RPM for 5min, the supernatant is removed and the cells are
resuspended in 1ml of cold PBS 1% FBS. The resuspended cells are then added to the prewashed MACS column, the CD43- cells that pass through the column and are collected in a
new 15ml conical tube. After the flow has stopped an additional 1-2ml of PBS 1% FBS is
added to the column and collected in order to collect any cells remaining in the column. The
CD34- cells are then counted with a hemocytometer for plating.

Primary Mouse B-cell culture
Primary mouse B-cells are cultured at a density of 200 x 105 to 1 x 106 cells per ml in
B-cell media, which consists of Roswell Park Memorial Institute media (RPMI) (SigmaAldrich, St. Louis, MO. Catalog #R8758) with 10% Fetal Bovine Serum (FBS) (SigmaAldrich, St. Louis, MO. Catalog# F6178), 1% Penicillin-Streptomycin (Sigma-Aldrich, St.
Louis, MO. Catalog #P4333) 10 mM HEPES (Sigma-Aldrich, St. Louis, MO. Catalog #
H0887) 10mM sodium Pyruvate (Sigma-Aldrich, St. Louis, MO. Catalog #S8636) 50µM 2mercaptanol (Sigma-Aldrich, St. Louis, MO. Catalog #M3148) mouse interleukin-4 (IL-4) at
g/µl (Sigma-Aldrich, St. Louis, MO. Catalog# I1020) Lipopolysaccharide (LPS) at
(Sigma-Aldrich, St. Louis, MO. Catalog# L2630).
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Retrovirus Production from BOSC23 cells
BOSC23 cells are grown and maintained in Dulbecco's Modified Eagle Medium
(Sigma-Aldrich, St. Louis, MO. Catalog #5796) (DMEM), 10% FBS (Sigma-Aldrich, St. Louis,
MO. Catalog# F6178), 1% Penicillin-Streptomycin. The BOSC23 cells are plated in a 6 well
plate in 2ml of media at a density of 200-250 x105 cells per well. 12-20 hours after plating
the cells are transfected with pCL-ECO and PMX using the Jet-prime transfection reagent
manufacturer’s protocol (Polyplus, Illkirch, France, catalog#114-07)
The media on the BOSC23 viral packaging cells is changed 12 to 24 hours after Jet-prime
transfection. Retrovirus containing supernatant is collected from the plate using a 5ml
syringe, and then filtered through a
Billerica, MA catalog#SLHV033RS). The virus can be used immediately, or aliquoted into
2ml Eppendorf tubes, and flash frozen on dry ice. Retrovirus containing supernatant is
collected at 48 hours, 60 hours, 72 hours, and 84 hours after the initial transfection. The
Frozen retro-viral supernatant is then stored at -80c for later use.

B-cell infection
Purified -CD43 mouse B-cells are plated in a 10cm plate at a density of 1 x 106 cells
per ml for 12-18 hours. The cells are then plated in a six well plate at a density of 1x106 cells
per ml in 1ml of B-cell media. 1ml of virus is the added to each well, along with 25µg/µl of
LPS, 10µg/µl of IL-4,

µg/ml 1M HEPES, and 2µl Polybrene (10mM) (Millipore, Billerica,

MA catalog# TR-1003-G). The cells are then spun at 1150g for 90min at room temperature,
then incubated at 37c for 12-24 hours, then 1ml of media is gently removed from the top of
each well, and replaced with B-cell media.
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Class Switch Recombination Assay
The infected B-cells counted daily and kept at a density of 5 x 105 per ml. At day 3
and day 4 post viral infection 1 x 106 cells are removed, transferred to a 1.5ml Eppendorf
tube, pelleted at 1500RPM and washed with 1ml of PBS 1% FBS. The cells are pelleted at
1500RPM and resuspended in 200µl PBS 1% FBS containing 1:1000 Rat anti-mouse IgG1APC (BD pharmagen, Franklin Lakes, NJ, catalog# 560089). The cells are stained for 20min
at room temperature. The cells are then washed with by adding 1ml of PBS 1% FBS, then
pelleted at 1500RPM. The cells are then resuspended in 500µl of PBS 1% FBS transferred
to a 5ml FACS tube, and kept on ice. The cells are then scanned on a BD LSR Fortessa
fluorescent cell analysis system.

IgG-cMYC Translocation Assay
30 x 106 B-cells are infected per group with retrovirus, counted daily and kept at a
density of 5 x 105 per ml in 10cm plates. At day 3 post viral infection the cells are collected
into a 50ml conical tube, washed with PBS and then resuspended in 4ml of PBS 1% FBS.
The cells are then transferred to a 4ml BD FACS tube scanned on a BD ARIA Fusion III
FACS sorter. Virally infected GFP positive cells are then sorted into a collection 15ml
collection tube containing 2ml of FBS.
To extract genomic DNA the cells are then washed with PBS, and pelleted at
1500RPM, then transferred to a 1.5ml Eppendorf tube and lysed with 200µl of SDS
Protease K digestion (Fisher scientific, Pittsburg, PA catalog# EO0491) buffer for at 12
hours at 55c. 500l of phenol is added to the tube. It is then vortexed and spun at 15000RPM
(or maximum speed). The aqueous (top) layer is then removed and transferred to a new
1.5ml Eppendorf tube. The DNA is then precipitated by adding 1ml of cold ethanol to the
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tube, which is then incubated on ice for 10min and spun at 15000RPM for 5min. The
majority if the ethanol is carefully removed, and 1ml of 70% ethanol 30% water is then
added and gently mixed to wash the DNA pellet. The tube is again spun at 15000rpm for
5min, and the majority of the liquid is carefully removed. To dry the DNA pellet completely
the tubes are left open over night at room temperature. The dry DNA pellet is then dissolved
in 100µl of nuclease free water, and the concentration is measured using a nanodrop 2000
(Thermo scientific).

Translocation PCR
Translocations are amplified using the Expand Long Range PCR System (Roche).
50μl
500ng of purified B-cell genomic DNA. The following derivative chromosome-15 primers
were used for the first round reactions, 5'-ACTATGCTATGGACTACTGGGGTCAAG-3' and
5' -GTGAAAACCGACTGTGGCCCTGGAA-3'. Cycling conditions for the first round PCR
were 29 cycles total with the first 10 cycles being 92c 10s, 60c 30s, 68c 7min. Followed by
19 cycles of 92c 10s, 60c 30s+20s each additional cycle, 68c 7min. First round PCR
reactions are checked for completion on a 1% agarose gel.
1μl of first round PCR reaction is used as the template for the second round PCR,
and derivative chromosome-15 primers 5'-CCTCAGTCACCGTCTCCTCAGGTA-3' and 5'GTGGAGGTGTATGGGGTGTAGAC-3'. Cycling conditions for the second round PCR were
25 cycles total with 10 cycles of 92c 10s, 60c 30s, 68c 4min, followed by 15 cycles at 92c
15s, 60c 30s+20s per cycle, 68c 4min. Second round PCR reactions are checked for
completion on a 1% agarose gel, and transferred to a transferred to a nylon membrane for
southern probing.
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Southern Probe for IgG cMYC Translocations
Second round translocation PCRs are run on a 1.1% agarose gel at 150v. The gel is
then visualized using a UV box to ensure that the second PCR worked. The gel is then
placed into a bath of denature buffer (1.5 M NaCl, 0.5 M NaOH) for 30min with gentle
agitation, then washed 2X with ddH2O, then placed in a bath of neutralization buffer (1.5 M
NaCl, 0.5 M Tris-HCL, 1 mM EDTA) for 30min with gentle agitation.
To transfer the DNA to the membrane a tub is then filled with paper towels or a large
sponge and soaked in 20XSSC buffer, the level of buffer should not be higher than the
height of the towels. A whatman filter is placed on the top of the paper towel stack. The gel
is then carefully placed on the whatman and a nylon membrane is placed on top of the gel.
3 to 4 more whatmans are placed on top of the membrane, and a large stack of dry paper
towels is placed on top. A large flat weight is then balanced on top of the stack, the whole
apparatus is covered in cellophane wrap to prevent dehydration. The transfer apparatus is
left at room temperature overnight to allow for complete transfer. After the transfer is
complete the apparatus is dismantled, the membrane is then washed with 2X SSC buffer for
5min and dabbed dry with a new whatman, and then placed in to a UV cross-linker for 3min
to bind the DNA to the membrane. The membrane is prepared for hybridization by
incubating in 10ml of hybridizaton buffer (50ml formamide, 25ml 0.5M NaH2PO4, 15ml H20,
5ml 5M NaCl, 7.0g SDS) with 200l of salmon sperm DNA (100X) in a hybridization tube at
55c for at least 1 hour. 1ml of buffer is removed from the tube and 600ng of probe is added
to it, the diluted probe is then added back into the tube. The membrane is probed with either
a biotinylated probe against cMYC (cMYC-15 Probe
3’-GGACTGCGCAGGGAGACCTACAGGGG-5’) or against IGH (IGH-15 Probe 3’CCTGGTATACAGGACGAAACTGCAGCAG-5’) probe is added and incubated at 55c with
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rotation overnight. Remove the blot from the tube and wash it 2XSSC+0.1%SDS for 20min
three times at 55c. The membrane is then incubated with blocking buffer (Casin, 1XTBST)
for 15min, then incubated with 70µl of streptavidin-HRP (300X) for 15min. The membrane is
then washed 4X with wash buffer (100mM Tris pH7.5, 150mM NaCl, 0.05% SDS) for 5min,
and then put into equilibration buffer (100mM Tris pH9.5, 150mM NaCl) for 5min. To
visualize the membrane excess buffer is removed, and 5ml of ECL is added, the membrane
is then placed into a cassette and exposed to a film in a dark room.

NTZ-3T3 Reversion Assay
NTZ-3T3 cells are maintained in DMEM with 10% FBS, and 1% PenicillinStreptomycin. Prior to the start of the experiment the cells are selected by treating with G418
at 1500µg/ml and Zeocin at 300µg/ml for 14 days. Cells are then removed from selection
pressure for at least 48 hours before starting the assay. To start the assay 1-2 x 106 NTZ3T3 cells are plated in a 10cm plate with 8ml of media, 12-20 hours later the cells are
infected with pMX-UNG-ΔGFP or pMX-ΔGFP by adding 2ml of retrovirus containing
supernatant and 10µl of Polybrene (10µg/ml). To select for pMX expressing cells, 48 hours
after infection the media is changed and the cells are treated with 4µg/ml puromycin (Sanata
Cruz Bio, Dallas, TX, catalog #sc-108071) for 48 hours. An uninfected NTZ-3T3 control plate
is also treated with puromycin to ensure that uninfected cells are killed efficiently. The media
is then changed to remove the cells from selection for at least 24 hours, the cells are then
passaged and replated in a 10cm plate at a density of 1-2 x 106 cells per plate in 8ml of
DMEM. 12-20 hours later the cells are infected with pMX-AID-mCherry 2ml of retrovirus
containing supernatant and 10µl of Polybrene (10µg/ml). The addition of AID virus is
considered to be Day 0, the starting point of the assay. The cells are then passaged at a
sub-confluent cell density and tested for GFP reversion on day 3 or 4, day 6 or 7, day 9 or
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10, day 11 or 12. To measure the percentage of GFP positive reverted cells at the
aforementioned time points, 1 x 106 trypsinized cells placed into a 4ml BD FACS tube,
washed with PBS 1%FBS, then resuspended with 1ml of PBS 1%FBS and scanned by a BD
Aria Fusion III Flow Cytometer to test for GFP expression. At the final time point of the assay
mCherry positive AID expressing cells are sorted by fluorescence activated cell sorting, and
collected in 15ml conical tube containing 2ml of FBS.

NTZ-3T3 Mutational Analysis
Genomic DNA Extraction
To extract genomic DNA the cells are then washed with 8ml of PBS, and pelleted at
1500RPM, then transferred to a 1.5ml Eppendorf tube and lysed with 200μl of SDS
Protease K digestion
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vortexed and spun at 15000RPM (or maximum speed). The aqueous (top) layer is then
removed and transferred to a new 1.5ml Eppendorf tube. The DNA is then precipitated by
adding 1ml of cold ethanol to the tube, which is then incubated on ice for 10min and spun at
15000RPM for 5min. The majority if the ethanol is carefully removed, and 1ml of 70%
ethanol 30% water is then added and gently mixed to wash the DNA pellet. The tube is
again spun at 15000rpm for 5min, and the majority of the liquid is carefully removed. To dry
the DNA pellet completely the tubes are left open over night at room temperature. The dry
DNA pellet is then dissolved in 100μl of nuclease free water, and the concentration is
measured using a nanodrop 2000.
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cDNA Synthesis
cDNA library generation for the cloning of genes was done using a SuperScript IV
Reverse Transcriptase Kit (Lifetechnologies, Waltham, MA, Catalog # 18090010) according
to the manufacturers protocol.

High Fidelity PCR
For every 20µl PCR reaction 100ng of NTZ genomic DNA is used. Along with 100ng
of forward primer CMVP-F TGACCTCCATAGAAGACACCCT and reverse primer tetGFP –R
TTATGTTTCAGGTTCAGGGGG. 100µM dNTPs, 2µl 10x Cloned Pfu AD reaction buffer,
and 1µl Pfu turbo DNA polymerase AD (Agilent technologies, Santa Cruz, CA. Catalog
#600255). Cycling conditions for the reaction are as follows 1X 94c 4min, 28X 94c 30s, 57c
30s, 72c 60s, 1X 72c for 4min. To add a Adenosine to the 3’ end the PCR product, 1μl of
Taq polymerase (Sigma-Aldrich, St. Louis, MO. Catalog #D1806) is added to the finished
PCR reaction and then it is incubated at 72c for 10min.
The PCR reactions is then run on a 1% agarose gel with 1µl/ml ethidium bromide. To obtain
pure GFP amplicons, PCR bands at 714bp are cut from the gel using a sterile razor blade,
and then digested using a GeneElute gel extraction kit (Sigma-Aldrich, St. Louis, MO.
Catalog # NA1111), and resuspended in nuclease free water.

TOPO-TA Cloning and DNA Sequencing
To isolate unique sequence clones for mutational analysis, purified GFP PCR
products were ligated into a plasmid vector for sequencing using a TOPO-TA cloning kit
(Lifetechnologies, Waltham, MA, catalog # 450071). To ligate the PCR product into the
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vector 2µl of purified PCR product is combined with 2µl of nuclease free water, 1µl of
manufacturer supplied salt solution, and 1µl of Topo vector solution. The reactions is
incubated for 10 minutes at room temperature, then placed on ice. 50µl of mach-1
competent e.coli cells are allowed to thaw on ice. 5µl of the TOPO ligation reaction is added
to the mach-1 e.coli cells and incubated on ice for 20min. The tube is then heat shocked for
30s at 37c, and placed on ice for 5 min. 200µl of SOCS media is added to the tube, and it is
placed in a 37c shaking incubator for 1 hour. 100µl of the Mach-1 cells in media is spread on
a LB agar plate containing 100µg/ml ampicillin. The plates are then incubated 12-24 hours
at 37c. Individual colonies are then picked using sterile pipet tips, placed in 10ml falcon
tubes, and incubated with 2ml of LB with 100µg/ml ampicillin at 37c with agitation overnight.
Topo plasmids are isolated from the overnight cultures using a GenElute plasmid
miniprep kit (Sigma-Aldrich, St. Louis, MO. Catalog #PLN70). Topo plasmids are then
resuspended in nuclease free water and their concentration is quantified using a nanodrop.
To analyze mutations plasmids are then sent to a sequencing core for Sanger sequencing
using M13 Forward primer 5’-GTAAAACGACGGCCAG-3’ and M13 Reverse primer 5’CAGGAAACAGCTATGAC-3’.

Site Directed Mutagenesis
20ng of mUNG or MHV-UNG in the pDUET plasmid were amplified by 0.5 μl of 25μM
each specific primer pair needed to mutate a specific amino acid to generate catalytically
inactive UNGs mixed with 5μl of 10X pfu turbo buffer, 1ul of 10mM dNTP mix, 1μl of pfu
turbo enzyme, and ddH20 to 50μl. The reaction conditions were as follows 18X 94c for 30
seconds, 55c for 1 minute, and 68c for 2 minutes. PCR reactions are then treated with 1l
DpnI for 1 hour at 37c. 2-10μl of each digested PCR reaction is then used to transform
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competent e.coli cells, which are then streak plated to produce single colonies. Individual
clones are analyzed by sequencing for the presence of the mutation. Once a vector has
successfully taken up a mutation, the vector is subjected to a second round of site directed
mutagenesis with the other primer pair and screened to produce a vector that posses both
desired mutations (Fig. 21). The sequences of the primers used to generate the mutations
are as follows:
mUNG D147N-F
5’-GGTTGTCATTCTGGGACAGaATCCCTATCACGGACCTAAT-3’
mUNG D147N-R
‘5-ATTAGGTCCGTGATAGGGATtCTGTCCCAGAATGACAACC-3’
mUNG H270L-F
‘5-CACCATGTCCTGCAGACAGCTCtCCCCTCCCCGCTGTCGGTG-3’
mUNG H270L-R
‘5-CACCGACAGCGGGGAGGGGaGAGCTGTCTGCAGGACATGGTG-3’
MHV68 D85N-F
‘5-GTTGTTATTCTGGGACAGaATCCCTATCATGGGGGCCAGGCC-3’
MHV68 D85N-R
‘5-GGCCTGGCCCCCATGATAGGGATtCTGTCCCAGAATAACAAC-3’
MHV68 H207L-F
‘5-CATCTTGTATTAAAGGCGCAACtTCCTTCCCCCCTGGCATCTC-3’
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MHV68 H207L-R
‘5-GAGATGCCAGGGGGGAAGGAaGTTGCGCCTTTAATACAAGATG-3’

Cell Lysis and SDS-PAGE
Frozen cell pellets are thawed on ice and resuspended in cold RIPA with protease
inhibitors (Roche, Indianapolis, IN, catalog# 04693116001) pipetted to insure complete
resuspension of the pellet. The suspension is then transferred to a pre-chilled 1.5ml
Eppendorf tube, and placed on a rocker at 4c for 10min. The tubes are then spun at 14,000
RPM for 5min at 4c, the supernatant is removed and placed into a new pre-chilled 1.5ml
Eppendorf tube on ice. The concentration of protein is then measured using a BCA protein
quantification kit (Fisher scientific, Pittsburg, PA catalog # 23228). Protein lysates are then
either stored at -80c or prepared for gel loading. 40g of protein per lane is mixed with 4X
NuPAGE LDS Sample Buffer (Lifetechnologies, Waltham, MA, Catalog # NP0007) 3µl of
NuPAGE sample reducing agent (Lifetechnologies, Waltham, MA, Catalog # NP0009) and
RIPA buffer to a final volume of 30µl and mixed, then heated to at 70c for 10min. After
heating the samples are loaded onto a 12% Bis-Tris gel (Lifetechnologies, Waltham, MA,
Catalog # GB00125) with 20X MOPS SDS running buffer (Lifetechnologies, Waltham, MA,
Catalog # NP0001), along with 20µl of Benchmark protein ladder for protein mass reference
(Lifetechnologies, Waltham, MA, Catalog # NP10747-012). Once the gel is fully loaded it is
run at 50mAmps for 40min or until the dye reaches the bottom of the gel.
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Gel to Membrane Protein Transfer
Once the Bis-Tris gel is finished running it is carefully removed from its plastic casing
and washed with Tobin’s buffer (25mM Tris, 192mM glycine, 10% methanol) the gel is then
placed onto a PVDF membrane that has been incubated in methanol. The gel and
membrane are then placed between two towbin’s soaked sponges, placed into a plastic
cassette and then placed into a XCell Transfer tank (Lifetechnologies, Waltham, MA,
Catalog #EI9051) containing cold tobin’s buffer. The proteins are then transferred to the
PVDF membrane at 400m Amps for 25min.

Western Blot
After the transfer the membrane is washed 3X in TBST (TBS 10% Tween 20), and
block with 5% milk 2% BSA in TBST on a rocker for 1 hour. The membrane is then washed
again with 3X with TBST. The membrane is incubated with primary antibody in 5% milk 2%
BSA for 1 to 12 hours, then washed 3X with TBST for 20 min. The membrane is then
incubated in secondary antibody for 30-60min in 5% milk and 2% BSA. Then the membrane
is washed with TBST 3X for 20min. To visualize the membrane it is exposed to 5ml of ECL
plus (Fischer Scientific, Waltham, MA, Cataloge#32132). After 1 minute of ECL exposure
the membrane is drained of excess ECL, wrapped in cellophane, taped into a cassette.
Films are exposed to the membrane in a dark room for 10s to 2 hours.

Two Dimensional Gel Analysis
Proteins were purified and prepared for analysis using methods previously published
(Shen, 2007). Proteins were separated by isoelectric point on a pH 3-10 immobilized pH
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gradient strip (Biorad laboratories, Phiadelphia, PA Catalog# 163-2032), Then separated on
a Criterion polyacrylamide gel (Biorad laboratories, Phiadelphia, PA Catalog# 345-0127)
before transferring to a nitrocellulose membrane and blotting with an anti-AID antibody (Cell
Signaling Technology, Danvers, MA, Catalog #4949) one hour to overnight.

FLAG Immuno-Precipitation
After cell lysis with RIPA buffer, 1-1.5ml of cold protein lysate is combined with 20μl
of Anti-FLAG M2 affinity agaros Gel Beads (Sigma-Aldrich, St. Louis, MO. Catalog #A2220)
and incubated with rotation at 4c for 1 to 12 hours. The beads are then washed 3X with
RIPA to remove non-precipitated proteins. To remove the bound protein from the beads
they are then mixed with 4X NuPAGE LDS Sample Buffer (Lifetechnologies, Waltham, MA,
Catalog # NP0007) 3µl of NuPAGE sample reducing agent (Lifetechnologies, Waltham, MA,
Catalog # NP0009) and RIPA buffer to a final volume of 30µl and mixed, then heated to at
70c for 10min. The precipitated lysates are then run on SDS-PAGE polyacrylamide gel, and
transferred to a nitrocellulose membrane for immunoblotting.
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Chapter 6 - Discussion
6.1 AID Phosphorylation
Our data, as well as the work of others, suggest that phosphorylation is a major
mechanism for regulating the activity of AID. Our analysis demonstrates that chromatin
associated AID is likely to be highly phosphorylated (Fig. 10). From these results we can
conclude AID’s phosphorylation state influences its ability to associate with chromatin and
act on genomic DNA. There has been notable interest in the study of AID regulation by
posttranslational modification, however the majority of research has focused on two
phosphorylation sites S3 and S38 (Delker, 2009). While these two sites have been shown to
be important in regulating the activity of AID in SHM and CSR, the signaling pathways that
lead to AID phosphorylation are not fully understood. Other studies have suggested that
protein kinase A (PKA) is capable of phosphorylating AID at S38, while our results
demonstrate the PI-3 kinase (PI3K) pathway can lead to phosphorylation of AID at this site.
These experiments should be interpreted cautiously though, since PI3K was able to regulate
AID-S38 phosphorylation in 3T3 cells but not in B-cells (Fig. 17). The modification state of a
protein can be complicated by a number of factors such as the phase of cell cycle, and
external growth factors, and cell type. Future study is needed if we hope to understand the
signaling pathways that regulate AID-S38 phosphorylation and their biological implications.
There are however many more post translational modification sites on AID such as
T150 and Y184 that have yet to be studied in detail. Our data suggest that these two sites
likely play a role in the regulation of AID in the CSR process (Fig. 13). How these sites
modulate AID’s involvement in CSR is still unclear. It is possible that these phosphorylation
sites play a role in the ability of AID to interact with binding partners. This may be an
important mechanism for regulating AID complex formation, catalytic activity or cellular
localization.
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The development of phospho-specific antibodies that recognize AID p-T150 or AID
p-Y184 will serve as an indispensable tool to study the effects of AID phosphorylation in the
future. While we have demonstrated their sensitivity and specificity (Fig. 11) the conditions
necessary for detection of these AID phosphorylation events are difficult to resolve. We
were able to stimulate AID-Y184 phosphorylation in mouse B-cells using NaVO4, a pan
tyrosine phosphatase inhibitor, then detect its presence by immunoblot (Fig. 12). Previous
studies had detected p-Y184 AID in mouse B-cells and our data confirms its presence
(McBride, 2006). Future work will focus on the determining the conditions that induce Y184
AID phosphorylation. Exposing B-cells to stimulation such as small molecule inhibitors, Tolllike receptor stimulation, or interleukins may stimulate Y184 AID phosphorylation, providing
insight into its role in cellular processes.
Perhaps the most informative model system for the study of AID phosphorylation
would be a knock-in mouse model system where the endogenous Aid is replaced with Aid
containing a point mutation that prevents phosphorylation at the site of interest. A knock-in
Aid-S38A mouse has already been generated, and an Aid-T150A or Aid-Y184F knock-in
mouse would provide great insight into the effect of these phosphorylation events in vivo
(Cheng, 2009). B-cells from these mice could be isolated for in vitro CSR experiments,
which would be less artificial than the viral transduction of AID in to Aid-/- B-cells. To detect
in vivo CSR defects, B-cells and serum from these mice could be analyzed for shifts in the
distribution of antibody isotypes. V(D)J sequences of germinal center B-cell from these mice
could be analyzed to detect defects in the SHM process. A transgenic model also has the
potential to produce an unexpected phenotype, providing information about the effect of AID
phosphorylation on physiological processes that would otherwise have remained unknown.
AID can be targeted to the V(D)J region or different switch regions of the Ig locus
depending on the factors present. Because of this AID interacting proteins are of intense
interest to the field. With the assistance of the Bedford lab, we were able to identify four
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potential p-Y184 AID binding proteins using a protein domain array (Fig. 14) These proteins
all contain a SH2 phospho-tyrosine binding domain, and two of them are themselves
tyrosine kinases known to be involved in B-cell signal transduction pathways (Zipfel, 2000).
A phosphorylation specific AID binding partner would be a novel discovery. This phosphospecific AID interaction could act as a mechanism to regulate AID’s dynamic roles at the Ig
locus. A unique signal, phosphorylation state, and phospho-AID complex to target AID to
each specific location on the Ig locus. Moreover it is still not know why AID induced uracils in
the Ig locus are repaired in a low fidelity manner. The phosphorylation state of AID, and the
binding partners associated with it, may serve as a switch to attract error prone repair
factors to the V(D)J locus.
Though mutation of the SH2 domain containing adaptor protein SH3BP2 is
associated with bone deformities in humans, its deletion from the mouse genome produced
an unexpected CSR phenotype, suggesting it may play a role in antibody diversification
processes (Chen, 2007). We were able to clone and isolate SH3BP2 from stimulated mouse
splenocyte cDNA, confirming its expression in B-cells. Using commercially available
antibodies we were able to detect SH3BP2 by immunoblotting HEK cells expressing pMXSH3BP2. However we were unable to detect SH3BP2 protein in lysates from stimulated
mouse B-cells. These results suggest that the currently available SH3BP2 antibodies are
unable to detect endogenous levels of SH3BP2. This limitation in sensitivity impeded our
attempts to detect p-Y184 AID SH3BP2 interaction in cells.
One strategy to overcome this limitation in sensitivity would be to detect p-Y184 AID
interaction with SH3BP2 using mass spectrometry. FLAG-AID expressing B-cells could be
treated with NaVO4 to prevent AID-Y184 dephosphorylation, then FLAG immunoprecipitated. Protein precipitates could then be analyzed by mass spectrometry to identify
AID interacting proteins; these results would be compared to cells expressing FLAG-AIDY184F
in order to identify proteins that interact specifically with p-Y184 AID.
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Although Sh3bp2-/- mice exist they have not been thoroughly evaluated for defects
in CSR or SHM. An in vitro CSR assay using Sh3bp2-/- B-cells would confirm the previously
reported CSR defect, and germinal center B-cells could have their V(D)J sequences
analyzed for defects in SHM. Sh3bp2-/- mice could also be crossed with other mouse lines
such as AIDY184F to determine if any detectable defects in B-cell processes are indeed do to
its phospho dependent interaction with AID.

6.2 The Role of Herpes Virus UNG
Previously it had been suggested that DNA viruses encoded UNGs in order to
protect their own genome from mutations caused by uracil incorporation. This has been
demonstrated in vivo in at least two systems in HSV-1 and MHV68 (Pyles and Thompson,
1994) (Minkah, 2015) . However, it was not known if viral UNGs were able to act on the host
genome and interfere with the action of host UNG. We have demonstrated viral UNGs are
capable of acting on uracils incorporated into mammalian genomic DNA in 3T3 cells, as well
as primary mouse B-cells. Not only are viral UNGs capable of eliminating uracils from
genomic DNA and triggering the downstream high-fidelity BER pathway, but they are also
capable of participating in complex antibody diversification processes in host B-cells.
When we introduced viral UNGs into Ung-/- mouse B-cells using a retroviral delivery
system all three of the viral UNGs tested, MHV68, EBV, and KSV were able to provide
compensation for the lack of mouse UNG in in vitro CSR assays (Fig. 18). While it is
possible that different viral UNGs may have differing levels of activity on the host genome,
all of the viral UNGs tested were able to induce a similar level of switch in this assay. If there
is any difference in the ability of these viral UNGs to induce CSR in
Ung-/- B-cells in vitro perhaps an experimental system that provides a lower level of UNG
protein expression would be able to reveal this difference.
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Our data demonstrates that when expressed in wild-type mammalian B-cells in vitro
viral UNG interferes with the CSR process, reducing its efficiency (Fig. 19). This unexpected
result demonstrates the importance UNG protein level in the CSR process. These data
suggest that there is an optimal level of UNG expression needed for efficient CSR; not
enough UNG and there will be little CSR, but too much UNG and switching efficiency will be
reduced.
The association of EBV infection with Burkitt’s lymphoma is well established and the
contribution of EBV genes such as LMP-1 and LMP-2 to EBV associated malignancies has
been heavily researched (Young and Rickinson, 2004). The discovery that viral UNGs may
be involved the transformation process is completely novel. Our data suggests that viral
UNG may protect the host genome from oncogenic translocations such as the IgH-cMyc
translocation associated with Burkitt’s lymphoma (Fig. 24). It is therefore possible that a loss
or down regulation of herpes virus UNG may be needed before oncogenic translocations
can occur. If herpes virus UNGs are indeed playing role in protecting the host genome from
mutagenic events as the data suggests, then they would be a poor choice to target with
drugs to treat viral infections.
The NTZ-3T3 indicator cell line has been previous used in studies to measure the
mutagenic activity of AID (McBride, 2006). As might be suspected the expression of viral
UNG in this system alongside AID significantly reduced the reversion rate of the STOP
codon (Fig. 27). Although it is not known if the presence of viral UNG in the system alters
the spectrum of mutations produced we are currently performing a clonal sequencing
analysis to address this question. The results of our CSR experiments demonstrate that
UNG may have an alternate protein scaffolding function independent of its catalytic activity.
In the future we plan to repeat the NTZ-3T3 mutation assay using the catalytically inactive
UNG mutants in order to study what, if any, effect this scaffolding mechanism has on the
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frequency of STOP codon reversion and the spectrum of mutations generated by AID
activity.
These experiments suggest that herpes virus UNGs may be interfering with AIDmediated antibody diversification mechanisms such as SHM and CSR, while protecting the
host cell genome from AID induced chromosomal instability. The pattern and levels of viral
UNG expression in infected host B-cells in vivo are unknown. Ascertaining the level of viral
UNG expression in vivo may prove to be a difficult task as there are no commercially
available antibodies that specifically recognize viral UNG. One possible approach to study
UNG expression levels in an in vivo model would be attach an epitope tag such as FLAG to
UNG in an MHV68 mouse model system, then isolating particular B-cell subsets such as
germinal center B-cells and immunoblotting their protein lysates using an anti-FLAG
antibody.
It would also be possible to epitope tag UNG in the EBV genome in order to study its
role using an immortalized human B-cell LCL system. An immortalized LCL system that
expresses an epitope-tagged viral UNG could prove to be a powerful system to study the
biochemistry of EBV-UNG in the presence of the full EBV viral genome and in the context of
its native host cell type. This system could potentially be used to identify potential EBV-UNG
interacting partners by immuno-precipitation, which would provide valuable insight into the
non-catalytic mechanisms of EBV-UNG action. An EBV immortalized LCL system could also
be used to study the effects of viral UNG on spectrum and frequency of mutations present in
the host B-cell genome, however this may not provide as much information as a full in vivo
system.
These data also provide insight into the molecular mechanisms of somatic
hypermutation and class switch recombination. The fact that expression of viral UNG or
mouse UNG in wild-type B-cells reduces switch efficiency suggests that UNG levels are
tightly regulated to an optimal level in the CSR process. The intriguing discovery that UNG
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catalytic activity is not necessary for this suppression of CSR efficiency suggest that UNG is
performing a non-cononical function, likely recruiting factors to the Ig gene locus through
protein-protein interaction. This alternate UNG mechanism may somehow contribute to the
shift to low fidelity repair mechanisms at the Ig gene locus, perhaps recruiting low fidelity
repair factors.
While these experiments demonstrate that it is possible for herpes virus to interfere
with the antibody diversification process it is still unknown whether this interference is used
as a direct mechanism to inhibit the immune response to the viral infection. It would certainly
be advantageous for a virus to prevent the host immune system from effectively responding
and adapting to its presence. Epstein Barr infection has been shown to be associated with
autoimmune disorders, suggesting that it does interfere with antibody formation in vivo, and
the discovery that viral UNGs interfere with antibody diversification processes in host B-cell
provides a potential mechanism for the formation of EBV associated autoantibodies
(Draborg, 2013). It may be possible to detect this influence of viral UNG on antibody
formation in vivo. By infecting mice with MHV68 or MHV68-ΔUNG virus then isolating B-cell
populations the antibody V(D)J sequences between these two groups could be compared. If
viral UNG alters SHM in vivo there may be differences between the frequency and spectrum
of mutations present in these two groups. Given the results from of our NTZ-3T3 indicator
cell line assay one might expect the MHV68-UNG expressing group to have less mutations
overall when compared to the MHV68-ΔUNG group. However it is possible that the
involvement of MHV68-UNG at the Ig locus alters the spectrum of mutations present, as the
mechanisms that lead to error prone repair at the Ig locus are not well understood. A mouse
model may serve as a better system to understand the influence of viral UNG on mutation
since cell lines such as the NTZ-3T3 cells may not express the necessary factors to initiate
error-prone repair in response to the removal of uracil from DNA. This system could also be
used to test for the effect of viral UNG on CSR in vivo. The data from in vitro CSR assays
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suggests that the presence of viral UNG interferes with molecular mechanisms of the CSR
process. However the in vitro assay provides limited information due to the fact that we are
only measuring the efficiency of switch from one isotype to another (IgM to IgG1), and that
viral UNG expression is driven off of an artificial promoter providing high protein expression.
It would be possible to measure the effect of viral UNG on the CSR process in vivo by
comparing infected B-cells from MHV68 and MHV68-ΔUNG infected mice. The frequency of
different BCR isotypes expressed on infected cells could then be measured by FACS
analysis. If the presence of viral UNG does indeed inhibit of the ability of B-cells to undergo
CSR one might predict that B-cells infected with MHV68-UNG expression would have
elevated levels of IgM expressing B-cells. An in vivo system such as this could also be used
to test the theory that herpes virus UNG interference at the Ig locus is actively involved in
suppressing ability of the host immune system to produce antibodies that recognize the
virus. Serum from MHV68 and MHV68-ΔUNG infected mice could be tested for its ability to
recognize MHV68 viral proteins via immunoblot assay.
Another possible explanation for the involvement of herpes virus UNG during SHM
and CSR is to promote survival and proliferation of the host B-cell. Herpes viruses that
target B-cells such as MHV68 and EBV possess a number of genes that stimulate growth
and survival of their host cell, allowing for replication of the episomal viral genome in the
process. AID expression is tightly restricted to germinal center B-cells where SHM and CSR
occur. EBV genes like LMP-1 and LMP-2 mimic and augment growth and survival signals
found in germinal center reaction reactions, In fact EBV LMP-1, which mimics CD40
stimulation, has been shown to up-regulate AID expression (Kim, 2013). While AID induced
mutations produce a diverse antibody repertoire they can also lead to programed cell death.
We have demonstrated that viral UNG is able to reduce the frequency of oncogenic
translocations (Fig. 24) that would most likely lead to apoptosis if they were to occur in wildtype cells in vivo. Viral UNG interference in AID-mediated processes may simply be a
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means for the virus to reduce the level of potentially genotoxic mutations, enhancing the
survival of the host cell and therefore the virus. This could be tested experimentally by using
an in vivo competition assay, infecting mice with wild-type MHV68 or MHV68-ΔUNG and
tracking each population with a unique label. After some length of time the ratio of wild-type
MHV-UNG to MHV68-ΔUNG virus expressing cells could be measured. If the infected cells
expressing MHV-UNG survive consistently longer than the MHV68-ΔUNG expressing cells it
would suggest that the presence of viral UNG does indeed provide protection to the host
cell.
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